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Hepatocellular carcinoma (HCC) is one of the top lethal cancers nowadays. 
Deregulation of MYC in HCC is frequently detected and always correlated with 
poor prognosis. In this study, we found that both of the two zebrafish myc 
orthologs, myca and mycb, are oncogenic. Moreover, the transgenic expression of 
myca in hepatocytes caused fast onset of tumors with divergent phenotypes and 
5% fish developed multinodular HCC with cirrhosis after 8 months expression of 
myca. Apparent apoptosis was also observed with myca expression. But 
introducing homozygous tp53M214K mutation into the myca transgenic fish could 
inhibit apoptosis and accelerate tumor progression. Nonetheless, the malignant 
status of hepatocytes relied on consistent expression of myca, which fast regressed 
after withdraw of myca expression, even in fish with tp53M214K mutation. Take 
together, our data demonstrate the robust oncogenicity of zebrafish myca, and also 
suggest zebrafish liver cancer model a potential application in human tumor 
studies and drug screening.   
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Chapter 1 Introduction 
1.1 Hepatocellular Carcinoma (HCC), the Malignancy of Hepatocytes  
Hepatocellular carcinoma (HCC), the malignancy of hepatocytes, is the most common 
primary liver cancer concentrated in Central Asia/Southeast Asia and sub-Saharan Africa 
and is one of the top three lethal cancers in the world (El-Serag 2012). As a serious tumor 
with the traits of late stage presentation, poor response to therapy and despaired prognosis, 
it becomes one of the hot research interests for oncologists and scientist.  
In human, HCC is a complex disorder syndrome, and the hepatocarcinogenesis is often 
associated with multiple risks factors. As early as in 1863, Rudolf Virchow has 
discovered the relationship between chronic inflammation diseases and malignant 
progression. Most of HCC cases are indeed originated from chronic inflammation. In 
contrast to acute inflammation which eliminates the infection/damage and serves as 
healthy guard, the chronic inflammation accumulates immune cells and consistently 
activates altered cytokine networks, which may cause necroinflammation and tissue 
remodeling and finally results in fibrosis or cirrhosis(Ramakrishna, Rastogi et al. 2013). 
As a consequence of chronic inflammation, the cell death and compensatory proliferation 
in fibrosis and cirrhosis is considered to be a prelude sign of most HCC (Ringelhan, 
Heikenwalder et al. 2013). 
The hepatitis virus infection is the most common cause of chronic liver inflammation and 
cirrhosis (El-Serag 2012). It has been reported that currently 350 million people are 
chronically infected with HBV (Hepatitis B Virus) while about 150 million people are 
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infected with HCV (Hepatitis C Virus) (Knolle and Thimme 2014). HBV/HCV infection 
is also considered to be the major risk of HCC initiation. There is a demonstrable link 
between HBV/HCV infection and HCC occurrence, as the HBV/HCV genome sequences 
are frequently detected in HCC patient with chronic HBV infection (Parkin 2006; El-
Serag 2012). Moreover, the virus infection caused chronic liver injury and host immune 
response subsequently develops into cirrhosis, which accounts for half of the HCC cases 
(El-Serag 2012). HBV infection itself also plays critical roles in HCC directly. For 
example, the HBV X protein (HBx) is indispensable in hepatocarcinogenesis progression 
because of its versatile functions, such as interaction with host transcription factors, 
proliferation promotion, as well as DNA repair suppression (Kew 2011). Although HBV 
virus genome usually persists as an episome, its integration into the host genome 
frequently occurs in infection(Jiang, Jhunjhunwala et al. 2012), and further induce DNA 
deletion, translocation and mutations, all of which are risks factors of HCC.  
In addition to virus infection, HCC is also associated with many other chronic damages. 
Chronic alcohol abuse is an important risk factor of HCC. Besides the direct injury to 
hepatocytes and subsequent inflammation, the alcohol metabolic intermediates such as 
acetaldehyde and free radicals exert numerous carcinogenesis effects, including alteration 
cell signaling pathways and increase DNA instability(Voigt 2005). HCC has also been 
related with many metabolic syndrome such as obese and diabetes. The accompanied 
insulin resistance and inflammation are all closely related with HCC initiation (Michelotti, 
Machado et al. 2013).  
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The transformation of normal cells into neoplastic state is complex which rises from 
genome instability and accumulation of genomic and epigenomic alterations. As 
summarized by Hanahan and Weinberg, the tumor cells adopts functional abilities of 
sustaining proliferation, evading growth suppression, resisting cell death, unlimited 
replication, inducing angiogenesis, activating tissue invasion and metastasis, as well as 
reprogramming of energy metabolism and  escaping from immune destruction(Hanahan 
and Weinberg 2011). The HCC also displays all this tumor hallmarks in its progression, 
and especially emphasizes some HCC specific features. 
Firstly, hepatitis virus infection increased genome instability and bring some mutation 
hotspots in HCC. It had been reported that the HBV integration occurs more frequently in 
the tumors than in the adjacent liver tissues in the HBV positive HCC samples (Sung, 
Zheng et al. 2012). Gene copy number variations, such as MYC gene, are also 
significantly increased near the HBV insertion sites (Sung, Zheng et al. 2012). Mutation 
bias have also been observed in HCC. For example, TP53 and CTNNB1 (β-catenin) are 
the most frequently mutated genes in HCC, while in contrast, KRAS activation mutation 
rarely occurs in HCC(Li and Mao 2013).  
Moreover, as a vital organ in the body, the liver not only plays a role in digestion, but 
also acts as a specialized lymphoid organ, and the specific microenvironment plays 
important role in oncogenesis. In response to damage and infection, hepatic stellate cells 
(HSCs) the liver-specific immune sensing cells, could produce the extracellular matrix 
and leads to fibrosis and cirrhosis(Krizhanovsky, Yon et al. 2008; Coulouarn and 
Clement 2014). Moreover, the cytokines produced by liver specific macrophages or 
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Kupffer cells, such as IL-6, could further promotes the inflammation and worsens 
transformation to HCC (Kmiec 2001; Stanculet, Grigoras et al. 2013). 
Finally, the liver is also the most important organ in metabolism and energy production. 
During tumor progression, numerous metabolites and metabolic networks in hepatocytes 
exhibits HCC specific remodellings. For example, the transition from mitochondrial 
respiration to cytosolic aerobic glycosis in HCC is much less than that in many other 
tumors(Beyoglu, Imbeaud et al. 2013). Furthermore, in contrast to the general 
consideration of de novo fatty acid synthesis in many other tumors, accumulating 
research data also indicated that fatty acid β-oxidation is increased in HCC, (Beyoglu and 
Idle 2013). These HCC specific modulations suggest more specific therapy plans are 
necessary for this tumor treatment.  
1.2 Myc and HCC 
1.2.1 Myc, the Global Transcription Factor 
1.2.1.1 Myc is a Global Transcription Factor 
Myc protein belongs to a transcription factor family which also includes Mycn and Mycl. 
The characters of this family are conserved sequence organizations shared by all the 
members. Myc was firstly identified as a DNA binding protein. The basic Helix-Loop-
Helix (bHLH) domain and Leucine Zipper (LZ) domain located in its C-terminal are 
directly involved in high affinity binding to the CACGTG E-box sequence (Blackwell, 
Kretzner et al. 1990). People also found that dimerization of Myc and Max, another 
protein containing the bHLH-LZ domains, in most circumstance is necessary for DNA 
binding(Nair and Burley 2003). Any changes in this bHLH-LZ structure could alter the 
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transcription activation ability of Myc. The N-terminal of the Myc protein is also called 
Transcription Activation Domain (TAD). Besides the nucleus localization signals, it also 
contains several highly conserved Myc Box (MB) motifs. It has been reported that Myc 
N-termianl recruits many co-regulators involving in histone modification, such as 
TRAAP (TRansActivation/transformation-Associated Protein) and GCN5(Liu, Tesfai et 
al. 2003). Some specific residues within the N-terminal directly contact with these co-
regulators and therefore are necessary for Myc transactivation (Liu, Tesfai et al. 2003). 
Hence, when the Myc-Max heterodimer and the other recruited cooperators form a 
complex and bind to DNA E-box, it then conducts chromatin modification, attracts RNA 
polymerase II (Pol II) and thereafter affects the transcription of target genes.  
Besides the Pol II related protein coding genes, Myc also can bind to non-E box DNA 
sequences and activate the RNA polymerase III (Pol III) transcribed genes. It is found 
that instead of the dimerization with Max, Myc is also associated with TFIIIB unit of the 
Pol  III directly. This interaction regulates the histone modification and activates the 
transcription of Pol III trarget genes, such as 5S rRNA, tRNA as well as other small 
RNAs(Gomez-Roman, Grandori et al. 2003; Kenneth, Ramsbottom et al. 2007). 
Moreover, Myc also directly enhances Pol I to control transcription of ribosomal RNA 
(rRNA) genes. The Myc-Max heterodimers has been found to be directly associated with 
ribosomal DNA, and inhibition of Myc-Max dimerization would affect rRNA 
synthesis(Arabi, Wu et al. 2005). Grandori and colleagues have reported that rapid rRNA 
synthesis is independent of Pol II and could be activated by conditional MYC-ER allele 
expression (Grandori, Gomez-Roman et al. 2005).  
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In addition to transcriptional activation, Myc also has been demonstrated to repress 
transcription, and genome-wide analyses have shown that Myc-repressed targets may be 
as many as the active targets (Meyer and Penn 2008). Although the study about 
repression is lagged behind that for activation, recently many studies have revealed that 
Myc-mediated transcription regression involves two main mechanisms. One is through 
the inhibition of some transcription activators, such as Sp1 and Miz1 by displacing their 
co-activators(Herkert and Eilers 2010). And the other is through chromatin modification. 
For example, Myc could recruit chromatin modification proteins such as DNA 
methyltransferase and histone deacetylase to suppress the gene activation(Peukert, Staller 
et al. 1997; Kurland and Tansey 2008). All in all, this Myc mediated repression is also 
necessary for its transformation and oncogenicity (Grignani, Lombardi et al. 1990),   
1.2.1.2 Myc Targets are involved in Many Cellular Process  
As a transcription regulator, the main problem of understanding Myc function is the 
identification of its target genes. Some techniques, such as ChIP-on-chip, high throughput 
sequencing of chromatin immunoprecipitation (ChIP-seq) or genomic marking methods 
enable the identification of the genomic binding sites and targets of Myc. The previous 
studies done with ChIP-on-chip have indicated that Myc could bind to about 10% to 15% 
genomic loci (Fernandez, Frank et al. 2003; Li, Van Calcar et al. 2003). The studies done 
with more precise ChIP-Seq narrow done the Myc binding site to bona fide candidates 
which still give rise to up to 7054 Myc binding sites in the Burkitt’s lymphoma cell lines 
(Seitz, Butzhammer et al. 2011). The expression profiling data have further supported 
that the transcription of most genes near Myc binding sites are directly related with Myc 
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expression (Patel, Loboda et al. 2004) and stimulate Myc protein expression also can lead 
to transcriptional up-regulation of its candidates (Danele, Reinhard et al, 2012).  
The majority of the genes near Myc binding sites are involved in critical cellular 
processes, such as cell cycle control, ribosomal synthesis, histone acetyltransferase and 
methytransferase complexes (Seitz, Butzhammer et al. 2011). Moreover, Myc up-
regulated targets mainly participate in cell growth, cell cycle activation, ribosome 
synthesis and so on(Luscher and Vervoorts 2012); while Myc down-regulated genes are 
those involved in attenuating cell cycle progression, such as cell cycle arrest, cell 
adhesion and contact(Luscher and Vervoorts 2012). In general, the expression profiling 
data indicate that Myc participates in both cell growth promotion and cell proliferation 
inhibiting abrogation, and these properties are apparently in agreement with myc 
oncogenicity.  
Moreover, Myc is also involved in transcriptional regulation through the interaction with 
transcriptional components. For example, after binding with E-box in the promoter region, 
Myc can stimulate the recruitment of the elongation factor P-TEFb (Rahl, Young et al. 
2014). Recently, Myc is also found to target all the active promoters and enhancers 
during transcription. This finding explains Myc’s broad oncogenicity in diverse tissues, 
because the expression of an existing tissue specific gene could be further amplified by 
Myc and result in uncontrolled accumulation of mRNA gene copies (Charles, Jakob et al. 
2012; Zuqin, Gangqin, et al. 2012). Although people still doubt the direct participation of 
Myc in this global transcriptional amplifier mechanism (Arianna, Theresia et al. 2014), 
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those studies proposed a more complex role of Myc in transcriptional regulation rather 
than an on-off switcher.  
Since the discovery of microRNA (miRNA) and its important role in many process, the 
regulation of miRNAs by Myc also rise as a research hotspot. Many studies have shown 
that miRNA is an important component of the Myc transcription regulation network, and 
Myc directly activates or suppresses many miRNA targets contributinh to tumorigenesis. 
For example, miR-9, which targets at E-cadherin-encoding mRNA, is upregulated by 
Myc in breast cancer cells to promote cell motility. Another example is miR-23a/b 
targeting at mitochondrial glutaminase(Ma, Young et al. 2010). In human P-493B 
lymphoma cells and PC3 prostate tumor cells, the deregulation of Myc results in decrease 
of this miRNA and lead to enhanced glutamine catabolism in tumor(Gao, Tchernyshyov 
et al. 2009). 
Finally, many recent studies have demonstrated that Myc may exert functions other than 
transcription activation. Dominguez-Sola and colleagues have showed that the binding of 
Myc to DNA stimulates DNA replication directly (Dominguez-Sola, Ying et al. 2007). 
Myc even can work independent of DNA-binding. For example, Cowling and Cole also 
found that Myc could facilitate the mRNA methylation directly. All these results suggest 




1.2.1.3 Myc Activation is Tightly Controlled 
Because of its important function in so many cellular processes, Myc activation is tightly 
controlled under normal conditions. The activation of MYC gene expression is the first 
level of regulation. In response to upstream mitogenic stimulations, such as SHH, WNT, 
TGF, etc., MYC gene transcription is greatly increased (Albihn, Johnsen et al. 2010; Milla, 
Cortes et al. 2012). Moreover, Myc activity is also regulated at the protein level, through 
the interaction with other proteins. For example, the Mxd family transcription repressors 
which also contain the bHLH-LZ domain could compete with Myc for available Max and 
E-box positions, and therefore restrict the activity of Myc (Hurlin, Queva et al. 1997).  
In addition to the Myc factor its own, the status of Myc targeted genes also affects the 
efficiency of Myc function. For example, epigenetic modifications of Myc target genes 
frequently happen in many physiological processes. The histone methylation at H3-H4 
and H3-K79 always indicates a site open for Myc binding(Guccione, Martinato et al. 
2006). Myc also prefers to active the genes have been previously active by other 
transcription factors whose epigenetic environment may favor the binding or Myc(Eilers 
and Eisenman 2008). 
Furthermore, as stabilized Myc could result in consistent activation of downstream 
transcription, degradation of Myc protein enables rapid turnover of its function. The Myc 
degradation is mediated by proteasome with the help of two ubiquitin ligases Fbw 7 and 
Skp2 (Welcker, Orian et al. 2004). Myc Box I plays a critical role in degradation, in 
which the phosphorylation of Serine 62 and Threonine 58 serves as a recognition site for 
Fbw7(Welcker, Orian et al. 2004; Welcker, Orian et al. 2004). The continue degradation 
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and replacement of Myc result in a short half-life of Myc of about 20 min (Ramsay, Evan 
et al. 1984) and guarantee only transient activation of its target genes. 
Finally, some of Myc activated genes form negative feedback loops to limit Myc over-
activation. miRNA may also be involved in this process. For example, miR-17-5p and 
miR-20a are activated by Myc, and they then target at E2F1 transcripts. As E2F1 is an 
important mediator to induce Myc expression, its inhibition would then reduce the 
amount of Myc (O'Donnell, Wentzel et al. 2005). 
1.2.2 The Oncogenic Potential of Myc 
The involvement of Myc in tumor development has been discovered for a long time.  
Actually, the first Myc gene v-myc was identified from MC29 avian tumor virus which 
can cause chicken leukemia myelocytomatosis(Duesberg and Vogt 1979). Then it was 
later found that the v-myc sequence might be captured from the host genome, and its 
cellular proto-congenic homolog in normal genome was identified and named as c-myc 
which is re-symboled to myc in gene bank database (Vennstrom, Sheiness et al. 1982).  
Myc deregulation is commonly detected in many tumors. For example, the MC29 virus 
infection results in either retroviral promoter integration in front of the genomic myc, or 
the virus v-myc insertion behind the genome promoter and form a chimeric v-gag-myc 
gene. Both cases lead to constitute expression of myc gene. Chromosome translocation is 
another major cause of myc deregulation. In Butkitt’s lymphoma, chromosomes 2, 14, 22, 
harbor the genes encode immunoglobulin (Ig) heavy and light chains, are translocated to 
chromosome 8. This recombination leads to Ig promoter to fuse with myc gene and 
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subsequently constitutive myc expression becomes the major cause of Butkitt’s 
lymphoma, T-cell acute lymphoblastic leukemia as well as multiple myeloma(Boxer and 
Dang 2001).  
Besides chromosome translocation, myc gene amplification is another common form of 
deregulation in most solid tumors. For example, amplification of myc has been found in 
breast and prostate carcinoma, and often it is a sign of poor clinical prognosis in clinical 
examination(Sato, Minei et al. 2006; Chen and Olopade 2008). Moreover, myc copy 
number alteration has been detected in both early and advanced human gastric cancer 
with no differences. This finding suggested that myc might be involved in carcinogenesis 
initiation of this tumor(Calcagno, Leal et al. 2008; Costa Raiol, Figueira Silva et al. 2008). 
Myc deregulation could also be at protein level. The up-regulation of myc expression as 
the consequence of upstream signaling pathways activation, increase the cellular 
accumulation of Myc molecules. Point mutations at Myc residue Thr58 and Ser62 could 
further strengthen Myc stabilization and also associated tumorigeneses(Thomas and 
Tansey 2011).  
1.2.3 Myc in HCC 
The increase of Myc activity plays a central role in the malignant conversion of 
hepatocytes. In human HCC, MYC gene amplification, the most common reason of 
deregulation, is frequently detected in tumors specimens(Takahashi, Kawate et al. 2007) 
and is also associated with tumor morphology and prognosis (Wang, Wu et al. 2002). 
Moreover, MYC amplifications in HCC patients are often related with serious tumor 
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grade and poor prognosis. More frequent MYC amplifications are detected in recurrent 
HCC (60%) and metastatic HCC (45%) than in the primary cases (38%)(Kawate, 
Fukusato et al. 1999; Wang, Wu et al. 2002).  
Besides genome instability and gene amplification, chronic liver injury also could lead to 
consistent deregulation of Myc. For example, significant elevation of MYC mRNA was 
associated with advanced liver fibrosis and cirrhosis in both human patients and mouse 
liver injury model (Nevzorova, Hu et al. 2013). The occurrence and aggravation of 
cirrhosis increase the risk of HCC. 
1.3 TP53 and HCC 
1.3.1 TP53 is Known as Tumor Suppressor 
It has been noticed for a long time that the incidence rate of most human tumor increases 
with age. This finding leads to the double-hit hypothesis, i.e. carcinogenesis, is the 
consequence of accumulated genomic DNA mutation. Both activation of an oncogene 
and inactivation of a tumor suppressor gene are critical steps in tumor initiation (Hanahan 
and Weinberg 2011). For example, activation of a proto-oncogene which stimulates cell 
proliferation, such as MYC, is one hit contributing to tumor initiation. Deactivation of a 
tumor suppressor gene which normally keeps proliferation and DNA damage in check, is 
another important hit in cancer development. A single hit to active proto-oncogene may 
not necessarily lead to tumor, as the tumor suppressor may initiate the apoptosis 
mechanism to eliminate the mutated cells.  
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1.3.1.1 The Structure and Regulation of TP53 
TP53 is one of the best known tumor suppressor genes and its mutation is detected in 
almost all kinds of cancer. Its protein product TP53 plays crucial role in DNA repair, 
proliferation regulation and apoptosis initiation. Similar to Myc, the TP53 is a multiple 
modular protein. The Transcriptional Activation Domain (TAD) and proline-rich domain 
(PRD) locates in the N-terminal of the TP53 protein(Joerger and Fersht 2008). Through 
the interaction with histone-modifying enymes, these N-terminal structures affect the 
transcription activity of TP53(Joerger and Fersht 2008). On the other hand, the lysine-
rich domain (LRD) at the extreme C-terminal serves for DNA binding. The most 
conserved domain is the central core from residues 100 to 300, which is responsible for 
sequence specific DNA binding and sensitive to missense mutations. Therefore, most 
TP53 mutations were found in this central core domain. Furthermore, six most common 
amino acid mutations in this region, R175, G245, R248, R249, R273 and R282 are 
identified as the hotspots mutations which are found in a variety of human solid tumors 
(Brosh and Rotter 2009). 
As a stress sensor, the pleiotropic role of TP53 in normal conditions is under controls. In 
response to cellular stress, such as DNA damage, oncogene activation and hypoxia, the 
protein kinase C δ interacts with Btf, a death-promoting transcription factor, and this two 
together bind to the core promoter element of TP53 to active its transcription(Liu, Lu et 
al. 2007). The function of TP53 also could be enhanced through the stabilization of its 
protein and increase its accumulation. For example, inhibiting the E3-ubiquitin ligase 
Mdm2 which targets TP53 for proteasomal degradation, could raise the TP53 induced 
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apoptosis (Brady and Attardi 2010). In general, both increased TP53 transcription and 
inducing its stabilization ensure its proper functions in response to cellular stress. 
1.3.1.2 The Function of TP53 
TP53 is considered as the “guardian of the genome” for its function in limiting mutation 
and cell damage. Similar to Myc, TP53 acts largely as a transcription factor. In response 
to cellular stress signals, TP53 protein tetramers are formed and are bound to DNA at 
specific sequences. This combination then stimulates the transcription of its downstream 
genes(Zilfou and Lowe 2009). If the damage is minor and repair is possible, TP53 could 
then activate the genes for cell-cycle arrest and DNA repair(Zilfou and Lowe 2009). In 
the case of sustained or sever damage, TP53-activated genes will trigger apoptosis and 
senescence process, such as the extrinsic and intrinsic death pathways (Brady and Attardi 
2010).  
Besides transcription activation, TP53 also repress gene expression. However, the 
mechanism of TP53in transcription repression is not as clear as its activation. It is 
believed that this process involves directly binding to specific DNA regulation elements 
and recruiting for histone deacetylases(Riley, Sontag et al. 2008). Moreover, TP53 could 
also directly regulate microRNAs encoding targets and then enable indirect repressions of 
many protein coding genes that participate in proliferation and cell cycle 
promotion(Corney, Flesken-Nikitin et al. 2007; Raver-Shapira, Marciano et al. 2007).  
The protein of TP53 is also implicated in many other cellular processes in addition to 
transcription regulation. It has been noted that the over expression of transactivation 
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incompetent TP53 protein mutants, where the DNA binding tetramer and transcription 
are destroyed, still could trigger apoptosis (Kakudo, Shibata et al. 2005). This suggested 
TP53 function may be independent of activation of targeted genes. Further studies have 
revealed that TP53 itself could directly promote the permeabilization of the mitochondria 
outer membrane and stimulate apoptosis (Moll, Marchenko et al. 2006). These 
transcription independent functions enable TP53 a double insurance as a cell guard. 
1.3.2 TP53 and HCC 
HCC is also considered to be subjected to a multistep process driven by accumulated 
genetic damages in hepatocytes and TP53 is one of the most frequently mutated genes in 
HCC. Moreover, TP53 mutations in HCC are always a sign of poor prognosis 
(Villanueva and Hoshida 2011). Many clinic studies have showed that the HCC patients 
with expression of mutant TP53 have shorter survival time (Liu, Ma et al. 2012; Ji, Wang 
et al. 2013). HBV/HCV infection and aflatoxin (AFB1) may be a major cause of TP53 
mutation in induced HCC. For example, more than half of HCC cases caused by AFB1 
exposure carry a R249S mutation in the 7th exon of the TP53 (Gouas, Shi et al. 2009). 
This R249S mutation is also prevalently detected in HCC patients with HBV 
infection(Kirk, Lesi et al. 2005). In addition to mutation, core proteins of hepatitis virus 
also can directly repress TP53 expression and diminish protein activity(Elmore, Hancock 
et al. 1997; Nishimura, Kohara et al. 2009; Moudgil, Redhu et al. 2013).  
Alteration of TP53 is the most frequent genetic changes in HCC and the protein TP53 
plays an important role in HCC progression. For example, TP53 expression is normally 
activated by variety oncogenes such as c-MET, MYC, NMYC and LDH-A and it in turn 
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represses these oncogenic signaling(Nilsson and Cleveland 2003; Hunten, Siemens et al. 
2013). The mutation of TP53 in HCC disturbs this auto-regulation loop and result in 
uncontrolled activation of oncogenic signal. Moreover, TP53 is newly found to be a key 
regulator of epithelial-mesenchymal transition in HCC and its knockdown significantly 
enhances metastasis (Wang, Jiang et al. 2013). On the other hand, restoration of wild type 
TP53 has been demonstrated an effective way to eliminate HCC tumors (Xue, Zender et 
al. 2007). Therefore, the above functions suggest TP53 an attractive therapy target.  
1.4 Oncogene addition 
Reversible neoplasm has been reported in both antisense-treated human cancer cell lines 
and conditional oncogene expression animal cancer models (Weinstein 2002). The 
phenomenon that the malignant status of some tumors is dependent on the sustained 
activation of specific oncogene is named “oncogene addiction” (Weinstein 2002). 
Addiction to Myc also has been reported in many studies. Such as the tet-off mice acute 
myeloid leukemia model, withdrawal of doxycycline lead to suspension of transgenic 
MYC expression and subsequent rapid regression of the tumor(Felsher and Bishop 1999). 
Even briefly inactivation of the transgenic MYC expression could result in sustained 
regression of osteogenic sarcoma and its differentiation into mature cell types(Jain, 
Arvanitis et al. 2002). However, people also noticed that not all the tumors could regress 
after the elimination of the original oncogenic factor, especially when additional 
oncogenic mutations have been occured during the tumor progression. For example, the 
mammary adenocarcinoma of a mice model established by overexpression of MYC, could 
not regress after MYC expression switch-off because of a secondary spontaneous 
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activating mutation in Kras(D'Cruz, Gunther et al. 2001). Therefore, it is attractive to 
investigate the tumor regression in myc transgenic fish and especially in the fish with 
tp53 homozygous mutation. 
1.5 Animal Model in Cancer Study 
1.5.1 Common Animal Models in Cancer Study 
To understand the fundamental mechanisms underlying cancer development and to 
discover effective therapies, direct investigation of the tumor biology is necessary. 
Generally, two strategies are employed in cancer studies. One is ex vivo study, which 
refers to the experiments conducted in controlled environment outside the living 
organism, such as tumor cell culture in plates(Teicher 2009). Therefore, the ex vivo study 
eliminates the disturbances of individual difference and has provided plenty of useful 
information about cancer. However, the achievements of ex vivo study are limited by the 
simplified and idealized environment. As cancer is a systemic disease involving different 
types of cells and spreading through many organs, the in vivo study, which is experiments 
conducted in a whole living organism, complementing the deficiency of ex vivo 
studies(Cespedes, Casanova et al. 2006; Teicher 2009; Ruggeri, Camp et al. 2014). 
Although compared with ex vivo, the in vivo study may be much more expensive and 
time consuming, it plays an essential role in understanding the fundamental mechanisms 
underlying tumor initiation, progression, and is especially necessary for the study of 
metastasis and antitumor agents screening(Berghmans, Jette et al. 2005; Liu and Leach 
2011; White, Rose et al. 2013).  
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Animal models that imitate human diseases are economical and convenient for in vivo 
studies. In general, there are three major ways to generate animal tumor models: 
transplantation, carcinogen treatment and genetic engineering. Transplantation is the 
easiest way to generate animal models of specific tumor types(Teicher 2009; Sampson, 
Kamara et al. 2013; Ruggeri, Camp et al. 2014). Usually it is transfer of tumor cells from 
a human cancer patient into immune deficient animals. The fast growth of tumor cells in 
animals enables in vivo analysis of human cells and is widely used for drug screening. 
The carcinogen induced animal models has been widely used in carcinogen screening and 
chemoprevention(Williams 2012; Vikis, Rymaszewski et al. 2013; Ruggeri, Camp et al. 
2014). However, the carcinogen derived tumor models are highly variable in tumor type 
presentation, and so hardly be used in high throughput study which requires a stable 
reproducibility. With the progression in cancer genome study in the past two decades, 
people noticed that gene alteration was the direct cause of tumor. Therefore, genetic 
engineered animal models established by modifying genetic information in the genome 
have been developed for more sophisticated in vivo study of tumors(Cespedes, Casanova 
et al. 2006; Sampson, Kamara et al. 2013; Ruggeri, Camp et al. 2014). Compared with 
the previous two techniques, genetic engineered animal model is much more expensive 
and time/efforts consuming, but it enables direct study the function of a particular 
oncogene in a particular organ. As the genotype is inheritable, the transgenic animal 
model can stably provide experimental animal individuals with similar phenotypes for 
long term studies. 
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1.5.2 Zebrafish, a newly Rising Animal Model for Human Cancer Study 
1.5.2.1 Advantages of Zebrafish as Cancer Model 
Rodents have long traditional applications in in vivo cancer study and provide plenty of 
knowledge of the tumor properties. Recently, several other animals, such as zebrafish 
(Danio rerio), have been developed for cancer study. Compared to the relative high cost 
of rodents, zebrafish have advantages of small size and low cost, so that they could be 
kept in large number in limited spaces(Berghmans, Jette et al. 2005; Liu and Leach 2011; 
White, Rose et al. 2013). As the experimental animal in this project, the biological 
properties and potential of zebrafish in cancer research will be introduced in detail as 
follows.  
The zebrafish has been a classical experimental model in development biology study for 
a long time. The property of low incidence of spontaneous tumor and being sensitive to 
many known human carcinogens suggest zebrafish also a potential model for cancer 
study(Spitsbergen, Tsai et al. 2000; Spitsbergen, Tsai et al. 2000). As a well established 
experimental model, the zebrafish has the unique merits over many other animals, such as 
good adaptability, high fertility and short generation time and so on. Moreover, both 
zebrafish and mammals are vertebrates and share highly conserved anatomical structures 
and homologous organs with similar physiological functions. Besides, majority of 
signaling pathways that govern proliferation, apoptosis, differentiation and cell 
movement are highly conserved between human and zebrafish at the molecular level(Liu 
and Leach 2011). The accumulated knowledge from developmental study and advanced 
technique tools further make zebrafish a mature platform for genetic manipulations. In 
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addition, the external development and transparent truck at embryo/larvae stage 
particularly ease of live imaging of belly cavity organs. Finally, as an aquatic animal, 
direct application of drugs in fish water allows all fish individuals evenly and equally 
contact with the molecules. All these traits make zebrafish a competent animal for cancer 
study and large scale drug screening.  
1.5.2.2 Current Application of Zebrafish in Cancer Research 
So far, several strategies have been employed to establish the zebrafish as cancer models. 
Carcinogen treatment has been adopted to induce zebrafish tumors since 1965(Stanton 
1965). The work of Spitsbergen in 2000 further demonstrated that zebrafish can develop 
a wide spectrum of cancers in almost all tissues and greatly resemble the corresponding 
human malignancies (Spitsbergen, Tsai et al. 2000; Spitsbergen, Tsai et al. 2000). Among 
these carcinogen induced tumors, liver is the primary target of most carcinogens. The 
liver tumor is also the most prominent neoplasm in carcinogen treatment which displays 
phenotypes similar to human HCC(Spitsbergen, Tsai et al. 2000; Spitsbergen, Tsai et al. 
2000). Furthermore, it has been showed that carcinogen induced zebrafish HCC not only 
resembles human HCC at histological level, but is also similar to human HCC in the gene 
expression profile(Lam, Wu et al. 2006).  
Another strategy to induce zebrafish tumor is genetic manipulation and targeted 
expression of potential oncogenes in specific organs. Compared to the non-specific tumor 
induction, low incidence and late onset of tumor in carcinogen treatment, the transgenic 
zebrafish cancer model allows direct assessment of a particular oncogene in a specific 
tumor type. For example, the first transgenic cancer model of zebrafish, T cell acute 
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lymphoblastic leukemia, has been successfully generated by expressing mouse Myc 
oncogene in T-cell under a T-cell specific rag2 promoter (Langenau, Traver et al. 2003). 
The GFP fused Myc oncogenic protein revealed the arising of leukemia in thymus and 
facilitated the tracing of tumor cells migration(Langenau, Traver et al. 2003). After this 
leukemia model,  more and more types of zebrafish cancer models have been successfully 
generated by transgenic approach, such as pancreatic neuroendocine tumors (Yang, 
Kutok et al. 2004), melanoma(Patton and Zon 2005), exocrine pancreatic cancer (Park, 
Davison et al. 2008), etc.  
In the past few years, several transgenic zebrafish liver tumor models have also been 
generated. Our lab and collaborators have generated the first zebrafish liver tumor model 
by overexpressing a zebrafish oncogenic mutant kras(V12) gene under a liver specific 
fabp10 (fatty acid binding protein 10) promoter(Nguyen, Emelyanov et al. 2011). It has 
been found that the tumor incident rate is related to the expression level of kras(V12) and 
the tumors cells are invasive to the healthy tissues when transplanted into a wild type fish 
(Nguyen, Emelyanov et al. 2011). Later, several other genes with oncogenic potentials 
such as xmrk, a nature occurred EGFRb mutated isoform, have been tested in the 
zebrafish platform by using inducible transgenic expression systems. With the induction 
of transgenic xmrk expression, rapid onset of liver tumor is induced in both larvae and 
adult zebrafish. It has also been found that the tumor status in these models relies on the 
sustained expression of xmrk, and the switch-off of the oncogene resulted in tumor 
regression to a normal status(Li, Huang et al. 2012). The mouse Myc oncogene has also 
been expressed in zebrafish liver to induce liver tumors by the inducible transgenic 
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approach, indicating a cross-species conservation of Myc oncogenicity(Li, Zheng et al. 
2013). Interestingly, although the gene expression profiles of these three zebrafish liver 
tumors have small overlaps with each other, they all displayed significantly correlation 
with a subset of advanced human HCC respectively and totally represent nearly half of 
the human HCC cases (Zheng, Li et al. 2014). A small set of deregulated genes (21 up 
and 16 down) shared by all these three transgenic fish, were also found in majority of the 
human HCC. These findings suggest that these transgenic zebrafish liver tumor models 
could resemble human HCC and especially be applicable in screening for oncogenic 
signaling specific drugs(Zheng, Li et al. 2014).   
1.6 Transgenic Expression Control Systems 
Using a tissue specific promoter to drive the oncogene expression in a specific organ is 
the most commonly used strategy to dissect the oncogene function in cancer progression, 
and several zebrafish tumor models have been established based on this method. 
However, the constitutive expression of oncogene could affect the proper development of 
the organ and cause high mortality at early stage. Most of the tumors will proceed to 
mature age and the tumor onset may damage the reproduction, and so the zebrafish are 
hardly maintained for long time study. To solve these problems, conditional expression 
systems have been designed to exert both spatial and temporal control of transgenic 
oncogene expression.  
1.6.1 Commonly used Gene Expression Control Systems 
The commonly used technique to enable conditional gene activation is binary transgenic 
systems. The general idea of the binary expression control is as following: the foreign 
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gene expression is controlled by a conditional promoter and is activated when particular 
conditions are met. For example, in the GAL4/UAS binary transgenic system, the foreign 
gene is downstream of the UAS sequence, which is a section of a promoter, while GAL4 
encodes the GAL4 transcription activator. The target gene expression will only be 
activated when the GAL4 transcription activator binds to UAS sequence. Usually, the 
GAL4 and UAS-target gene are separated into two transgenic lines, and thus, the parental 
line with the silent oncogene can be maintained easily (Ornitz, Moreadith et al. 1991). 
Another example of binary expression control is the Cre-loxP system. Cre is a protein 
mediated site-specific DNA recombination and LoxP is the recombination signature 
sequence which can be recognized by Cre. The encounter of Cre with LoxP will cause 
DNA recombination between two LoxP sites (Sauer 1998). In practice, a stopper 
sequence is put in between the two LoxP sites, and the whole construct is then inserted in 
between the promoter and the foreign gene. Therefore, only when Cre proteins are 
present and trigger the combination to remove the stopper sequence in between LoxP site, 
the foreign gene expression will be activated. However, limitations of this simple binary 
control also exist. For example, high level of GAL4 accumulation has been proved be 
toxic and affect development process, and so the GAL4/UAS system are not suitable for 
embryo study (Habets, Clout et al. 2003; Scott, Mason et al. 2007). However, as the Cre-
LoxP recombination is an irreversible process, the foreign gene expression cannot be 
switched off, and so it is not suitable for tumor regression study. 
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1.6.2 Mifepristone Inducible LexPR System 
Chemical-inducible binary expression techniques make both temporal and spatial control 
of gene expression feasible. Furthermore it allows reversible turn-on and off of the target 
gene expression. Many chemical-inducible systems have been designed, and in this 
project, the mifepristone-inducible LexPR system (Emelyanov and Parinov 2008) was 
employed to control the expression of transgenic oncogene in zebrafish liver.  
The mifepristone-inducible LexPR system consists of two basic elements, as shown in 
Figure 3-1: a chimeric transcription factor, the LexPR transactivator, and a cis-acting 
operator-promoter, the LexOP. The LexPR transactivator is a fusion protein consisting 
three parts, the ligand binding domain from human progesterone receptor, DNA binding 
domain from bacterial LexA protein and the transcription activation domain from human 
p65 transcription factor (LexDBD-PBLBDΔ-p65AD). LexOP operator directly controls the 
expression of transgene. However, as it is only a small piece of DNA consisting of a 
synthetic LexA operator and a minimal 35S viral promoter, the LexOP operator alone is 
not sufficient to active the expression of the transgene. Thus in LexOP operator, there 
locates the binding site for the LexPR transactivator. With the presence of the 
progesterone antagonist mifepristone, the chimeric LexPR transactivators dimerize and 
bind to the LexOP operator and then active the transcription of the downstream 
transgenic gene.  
1.7 Main Objectives and Significance of the Study 
The studies of human MYC have revealed its tight relationship with many kinds of 
cancers. MYC amplification and deregulation are also been detected in HCC. As an 
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emerging animal for human cancer study, many successful tumor models have been 
successfully generated in zebrafish. However, so far there is no study to investigate the 
function of zebrafish myc product and its involvement in liver tumor initiation and 
progression. The research gaps for the current study in this area are summarized below: 
 Zebrafish harbors two orthologs of human MYC, myca and mycb. Whether both 
zebrafish orthologs are oncogenic and whether they are equally oncogenic are 
unknown. 
 As an important tumor marker gene in HCC clinical diagnoses, human MYC is 
tightly related with fast tumor progression and poor prognosis. However, whether 
it is also an initiative factor of HCC has not been clearly studied.  
 Strong apoptosis signals have been observed in the MYC deregulated cell 
lines(Hoffman and Liebermann 2008). The involvement of TP53 in Myc caused 
apoptosis also has been demonstrated(Amaral, Xavier et al. 2010). Nevertheless, 
whether TP53 mutation affects Myc oncogenicity in HCC has never been studied. 
The aim of this project was establishing a zebrafish liver cancer model by overexpressing 
GFP fused zebrafish myc genes in the fish liver under the control of mifepristone LexPR 
system. The specific objectives of this project are presented as follows: 
 By overexpressing myca in zebrafish liver, the questions that whether HCC could 
be triggered by myca activation will be investigated. 
 A comprehensive comparison study about the tumorigenicity of zebrafish myca 
and mycb will be performed in this project.  
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 Transgenic myc cancer models will be generated in a zebrafish line with 
homozygous TP53 mutation background to investigate the impact of TP53 on 
myca oncogenicity in tumor progression.  
This study will be the first in vivo study of the zebrafish myca and mycb. The 
comparative functional and oncogenic study of these two zebrafish myc orthologs may 
provide an evolutional view of oncogene function. Moreover, the project will also be 
novel because this is an in vivo study of Myc and TP53 pathway crosstalk. It may lead to 
the answer whether mono-oncogene promotes serious HCC and how tumor suppressors 
affect this process. In the next chapter, the experimental techniques used in this study will 
be present.   
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Chapter 2 Material & Methods 
2.1 Zebrafish Maintenance 
2.1.1 General Fish Maintenance  
All the transgenic fish in this experiment were generated from the wild type zebrafish AB 
strain, which was obtained from Zebrafish International Resource Center (ZIRC) and 
maintained by Temasek Life science Laboratory fish facility.  
The adult zebrafish were maintained according to the established protocol described by 
The Zebrafish Book (Westerfield 2007). Usually about 20 to 30 fish were kept in a 2.5 
Liter aquaria tank. The aquaria were kept at a constant temperature of about 28 °C, and 
the fish were raised in fish water (60 μg instant ocean sea salts per 1 ml distilled water) 
with sustained cycling and filtering. The whole facility was in a controlled artificial 
photoperiod cycle at 14 hours of light and 10 hours of dark, which is suitable for fish 
spawning. Normally, the adult zebrafish, above 1 mpf (month post-fertilization) were fed 
twice a day at 9 am and 5 pm with Artimia nauplia (Brine shrimp) and once per day at 11 
am with flake food (Aquori, USA).  
Zebrafish reach sexual maturity in about 3 months with the above feeding schedule. 
Usually fish of 6 to 18 months old were used for breeding. To make a maximum embryo 
production, the fish for breeding were fed with flake food 1 – 2 hours before the end of 
the light period and then setup for mating (Westerfield 2007). The zebrafish in mating set 
usually produce embryos the next morning shortly after sunrise.  
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Embryos were collected from the bottom of the mating tank with embryo siphon or net. 
About 50 embryos were raised in egg water (2 ml of 0.1% methylene blue per 1 liter fish 
water) in 28 °C incubator till 5 dpf (days post fertilization). Unfertilized eggs/dead embryos 
were removed at 12 hpf (hours per fertilization) and 24 hpf. The fish were started to be fed 
with fine grinded flaked food since 5 dpf, and baby brine shrimp was added in from about 20 
dpf, and adult foods were fed as soon as they were big enough. 
All experiments involving animals were approved by the Institutional Animal Care and 
Use Committee (IACUC) of the National University of Singapore. 
2.1.2 Mifepristone Preparation  
The expression of the LexPR system is activated by mifepristone (RU-486, SIGMA-
ALDRICH #M8046). Mifepristone were firstly dissolved in ethanol to get stock solution 
(20 mM). This stock mifepristone were added into fish water to prepare the final 
concentration to induce transgenic oncogene expression. 
2.1.3 Transgenic Fish Generation and Maintenance 
Two basic transgenic fish lines, Driver line and Effector line, were used in this study and 
both were generated using the Ac/Ds transposon system (Emelyanov, Gao et al. 2006). As 
detailed showed in Figure 3-1, the Driver and Effector fragments were inserted between 
two Ds cis-required sequences(Emelyanov and Parinov 2008) and the whole sequences 
were cloned into the pBluescript SK(+) vector. 10 pg of above construct DNA was co-
inject with 40 pg in vitro synthesized transposase mRNA at 1-2 cell stage of zebrafish 
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embryo development(Emelyanov and Parinov 2008), and then the embryos were raised 
up for founder screening. 
The Effector line could express mCherry in the eyes without any induction, and therefore 
could be selected directly at about 2 dpf under a dissection microscope with RFP channel. 
The Driver line could express GFP in zebrafish liver with the induction of mifepristone. 
To screen this fish, the larvae were induced with 0.5 μM mifepristone from 3 dpf when 
the liver bud emerged, and then the larvae were screened under the GFP channel of a 
dissection microscope at about 2 dpi/ 5 dpf. The selected GFP-positive larvae were then 
washed with fresh egg water and transferred to larva tanks and raised up in mifepristone-
free fish water according to the method described in section 2.1.1. The double transgenic 
fish were generated by intercrossing the Effector fish with the Driver fish. They were 
firstly screened for mCherry at 2 dpf, and then induced with 0.5 µM mifepristone at 3 dpf 
and screened for GFP positive at 5 dpf. The double transgenic line were named after the 
oncogene it carry, such as mycAG line is the double transgenic line carries the myca 
oncogene fused with GFP. F2 fish from F1 generation incross were used for the 
experiment which is a mixture of heterozygous and homozygous. 
2.1.4 Transgenic Line Genotyping 
The F1 Effector line fish were re-generated by outcrossing the F0 generation with wild 
type fish. Then each individual F1 mycAG Effector fish and F1 mycBG Effector fish was 
outcrossed again with the wild type AB strain or Driver fish. Expressing mCherry in eyes 
was the marker for Effector offsprings. Accordingly, the numbers of offspring with 
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mCherry eys were recorded. The possible genotype of Effector lines analyzed in the 
statistic method described in section 2.6.2. 
2.1.5 Generation of mycAG Transgenic Fish with tp53M214K Homozygous Mutation  
The mycAG transgenic fish with tp53M214K homozygous mutation were generated by 
intercrossing mycAG transgenic fish with the tp53M214K homozygous mutant (tp53-/- in 
Figure 2-1) and offsprings of this cross were all tp53M214K heterozygous (labeled as 
“mycAG tp53+/-” in Figure 2-1). These heterozygous offsprings were raised up for 
incrossing. According to Mendelian inheritance, ¼ offsprings from these heterozygous 
incrossing would be tp53M214K homozygous mutation. Using the primers which cover the 
mutant site in the 3’ end (Berghmans, Jette et al. 2005), the offsprings from heterozygous 
incross were genotyped at 3 mpf. The fish with both mycAG effector fish phenotype 
(mCherry in eyes and GFP in liver with mifepristone induction) and homozygous p53 
mutation were selected as the founder F0 and were named as AG53 line. The F0 AG53 
fish were then incrossed to generate F1 which were also genotyped at 3 mpf. As 
anticipated, 100% of the F1 fish incrossing offsprings were tp53 -/- homozygous 
mutation. The AG53 fish were directly used for tumor induction according to procedure 
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in Section 2.1.3 and 2.1.4. 
 
Figure 2-1. The Scheme to Generate AG53 Fish Line.  
A. tp53M214K mutation is located at the DNA binding domain of the zebrafish tp53 protein. 
Primers were designed to distinguish this mutation from the wild type.  
B. The scheme to generate AG53 fish.  
C. An example of genotyping PCR products for agarose gel screening: L, Ladder; W, PCR 
product of wild type tp53; M, PCR product of mutant tp53M214K; N, negative control without 
genome DNA template. 
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2.1.6 Gross Examination of Tumorigenesis 
The zebrafish liver morphology in both larvae and adult was observed under a dissection 
microscope in both bright and GFP fields. The movement and twitch of zebrafish started 
from about 19 hpf; therefore, to take a stable and clear image, anesthetic was necessary in 
both larvae and adult zebrafish manipulation. The anesthetic were conducted according to 
the process described in ZFIN The Zebrafish Book(Westerfield 2007): the stocking 
anesthetic solution were prepared by dissolving 400 mg Tricaine (3-amino benzoic 
acidethylester) (Sigma, USA) powder in 97.9 ml of sterile water and the pH was adjusted 
to 7 using Tris pH 8.0. The working solution was generated by mixing 4.2 ml of stocking 
solution with about 100 ml egg water or fish water. The embryos would stop moving 
after a few second and be ready for microscope observation. To anesthetic adult fish may 
take a longer time of about 30 s and the sign of successful adult anesthetic is no 
movement of the gill. If the fish were not for sacrifice, observation and imaging process 
should be carried out within 3 minutes, while long term anesthetic would be harmful. 
The zebrafish larvae were transparent and the liver with GFP signal could be observed 
directly under microscope. The adult zebrafish trucks were opaque and dissection to 
expose the abdominal organs was necessary. The live gross morphology, such as color, 
size and shape were examined under the bright field of Nikon SMZ1600 
stereomicroscope (Nikon Instruments). Fluorescent images were taken by Nikon 
DXM1200F digital camera with MetaVue bioimaging software (Molecular Devices, 
Sunnyvale, CA). If liver tumors were present, after imaging, the tumor tissues were 
collected for RNA extraction, protein sampling, and histological assays. 
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2.1.7 Measurement of Liver Size 
Zebrafish liver lies in the left side of the body. To take a full image of the liver, the 
zebrafish larvae were put in a thin layer of 3% methyl cellulose (Sigma, M-0387) and let 
the left side facing up. All the larvae were photographed at the same magnification and 
exposure time. The liver shape in larvae was clearly visualized in GFP. As the GFP area 
could be calculated in pixels by bio-image processing software ImageJ (Java-based 
Image Processing Program, NIH, U.S.), the liver size of larvae from different treated 
groups were compared by T-test in Excel.  
2.2 Sequence Analysis 
2.2.1 Sequence Alignment 
Protein sequences of human MYC, mouse Myc, zebrafish myca and mycb were obtained 
from NCBI according to their accession numbers. The important domains were classified 
based on human MYC sequence. The selected sequences, including the whole sequences 
and sub-domain sequences, were submitted to EBI Clustal Omega Multiple Sequence 
Alignment software (web version http://www.ebi.ac.uk/Tools/msa/clustalo/). The 
returned alignment results were further adjusted manually through Jalview (Desktop 
version 2.4).  
2.2.2 Phylogenic Tree Generation 
Sequence phylogenic tree was calculated based on the Neighbour Joining algorithms by 
Jalview Desktop version 2.4 “calculate => calculate tree” submenu. The input data 
includes both the whole sequence alignments and sub-domain sequence alignments. The 
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relationship between each sequences and the ancestor was demonstrated in evolutionary 
distances. 
2.3 General Molecular Biological Techniques 
2.3.1 RNA Extraction 
Before RNA extraction, all the utensils in the process were immersed with 0.1 % DEPC 
solution for 2 hours and then autoclaved to eliminate DEPC remnant. All the solutions in 
the RNA extraction were also prepared with DEPC treated water. 
After fish dissection and tumor observation, the liver sample for RNA extraction was 
firstly kept in TRIzol® Reagent (Invitrogen #15596-018) on ice. After homogenizing and 
3 to 5 minutes incubating at room temperature, 1/6 volume of chloroform was added and 
the tubes were shaked vigorously by hands for about 30 s till the whole solution turned 
into even pink color. The tubes were then stood still at room temperature for about 3 to 5 
minutes till the solution was divided into two layers. The tubes were then centrifuged at 
12000g for 15 min at 4 °C and the upper aqueous phase containing RNA was transferred 
to a fresh tube and RNA was then precipitate by adding 0.75 volume of ice-cold 
isopropyl alcohol. After gentle mixing and 10-min incubating at room temperature, the 
tubes were sent for 10 min 12000 g centrifuge at 4 °C. To collect the RNA pellet, the 
supernatant was discarded and the RNA pellet was washed twice with 75% ethanol 
followed by centrifugation. Finally, air dried the RNA pellets were dissolved in about 20 
to 50 ìl DEPC treated water.  
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RNA concentration was measured by NanoDropTM 3300 (Thermo Scientific, Wilmington, 
DE), in which one unit of A260 is equivalent to 20 ìg/ml of RNA. The integrity of the 
RNA samples was evaluated by UV spectrophotometry. A260/A280 ratios around 2.0 
indicate good quality of RNA products. The purified RNA samples solution were stored 
in -80 °C fridge.  
2.3.2 Reverse Transcription PCR (RT-PCR) 
The RNA samples for RT-PCR were firstly treated with DNase I (InvitrogenTM, Cat. No. 
18068-015). For a 10 ìl reaction, up to 3 ìg RNA sample could be completely cleaned.  
The DNase I treated RNA was used for first strand cDNA synthesis according to the 
protocol of SuperScirptTM II Reverse Transcriptase kit (Cat. No. 18064-022). 1 ìl  
Oligo(dT)12-18 (500 ìg/ml) and 1 ìl dNTP (10 mM each) were added into the purified 
RNA, DEPC water was added to 12 ìl. The mixture was heated to 65 °C for 5 min and 
then quickly chilled on ice. The content was collected by brief centrifugation and 4 ìl of 
5× reaction buffer and 2 ìl of 0.1M DTT were added. The solution was mixed gently and 
incubated at 42 °C for 2 min. Finally 1 ìl of SuperScriptTM II reverse transcriptase and 1 ìl 
DEPC water were added and mixed gently. The tubes were then incubated at 42 °C for 50 
min for cDNA synthesis and finally stopped by heating at 70 °C for 15 min. The cDNA 
samples could be stored in -20 °C for months.  
2.3.3 Primer Design & Quantitive PCR (qPCR) 
The primers for real-time PCR were designed by NCBI Primer-BLAST web tool and the 
primers were picked up according to the following criteria: Firstly, the real-time PCR 
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amplicon size should be about 230 to 250 bp; secondly the primer melting temperatures 
should be 58 °C to 62 °C; thirdly the primers must have at least 2 total mismatch to the 
unintended targets and the 2 mismatches should locate within the last 5 bp at the 3’ end; 
finally the primers span an exon-exon junction have priority in selection. To distinguish 
the endogenous myca and mycb from the transgenic mycAG and mycBG genes, one 
primer was required to locate in the 3’ untranslated region (3’ UTR) or 5’ UTR of the 
endogenous myc. To detect the expression of transgenic mycAG and mycBG genes, the 
primers were required to span the gene coding region and the GFP coding region. All the 
primers used in real-time PCR are listed in Table 2-1. 
The cDNA were diluted 20 to 50 times for qPCR. Normally a 10 ìl reaction volume were 
used for reaction, which includes ddH2O, 1 ìl of diluted cDNA as template, 0.5 ìl each of 
the forward and reverse primers (10 μM each), and 5 μl 2× FastStart SYBR Green Master 
(Roche Applied Science, # 04673484001) containing FastStart Taq DNA polymerase, 
reaction buffer, dNTPs, and SYBR Green I. The real-time reactions were conducted by 
the LightCycler® 480 Instrument II. Usually, a complete reaction has 40 cycles and one 
cycle includes denaturation at 95 °C, annealing at about 58 to 62 °C depending on the 
primers, and finally extension at 72 °C. The reaction is followed by a melting curve 
analysis as described in the manufacturer’s protocol. Each sample had two or three 
replicates, and the expression of â-actin I was used as the internal control. 
Gene expression level was calculated according to the ÄÄCt method. Firstly, the cycle 
numbers (Ct) of replicates were averaged. Then they were all normalized with the cycle 
cumber of the â-actin I to get the ÄCt according to the equation “ÄCt = Ct gene of 
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interest – Ct â-actin I ”. The final gene expression values were calculated using the 
equation “relative expression of a gene of interest = 2^-ÄÄCt = 2^-[ÄCt transgenic 
sample –ÄCt control sample] = 2^-[(Ct gene of interest – Ctâ-actin I)transgenic sample – 
(Ct gene of interest – Ctâ-actin I) control sample]”. In the endogenous myca/mycb and 
transgenic mycAG/mycBG genes comparison, the “ÄCt control sample” was the average 
ÄCt of the endogenous myca in the control sample. 
 
 
2.3.4 DNA Extraction for tp53M214K Mutation Genotyping 
DNA were extracted from fish scales or fin clips for genotyping. Adult zebrafish were 
anesthetized using Tricaine according to the method in Section 2.1.6. The completely 
anesthetized fish was placed on a clean petri dish. A corner of the tail was cut with a 
surgical razor blade, or several pieces of scales were collected from fish back by surgical 
forceps. After sampling, each fish was kept in a recovery tank individually. 2 ml of 0.1% 
methylene blue was added per 1 liter fish water to prevent potential infection. 
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The collected tissues were kept in DNA extraction buffer (10 mM Tris pH8.2, 10 mM 
EDTA, 200 mM NaCl, 0.5% SDS, 200 µg/ml Proteinase K) and homogenated gently. 
The samples were then incubated at 55 °C for at least 3 hrs with vortex occasionally. 
Equal volume of phenol and chloroform (1:1) were added and mixed thoroughly and 
gently. After 10 min centrifugation at 12000g, the upper layer was transferred into a new 
tube. Equal volume of chloroform were added and mixed to further purify the DNA.  
After another 10 min centrifugation at 12000g, the upper layer was collected. The 
genomic DNA was then precipitated using 0.1volume of sodium acetate and 2.5 volume 
of absolute ethanol. The DNA precipitates were washed twice with 70% ethanol. The air 
dried DNA was dissolved in 10 to 50 µl TE buffer (1% sodium dodecyl sulfate 5 mM 
EDTA, 10 mM Tris-HCl pH 7.4.) depending on the DNA amount. 
DNA concentration was measured by NanoDropTM 3300 (Thermo Scientific, Wilmington, 
DE). One unit of A260 is equivalent to about 50 ìg/ml of double strands DNA. The 
integrity of the DNA samples was evaluated by UV spectrophotometry. A260/A280 
ratios around 1.8 indicate good quality of DNA. The DNA samples were stored at -20 °C. 
2.3.5 PCR Reaction & Genotyping 
To distinguish the tp53M214 mutant from the wild type, the reverse primers have one 
nucleotide difference at the 3’ end. The genotyping PCR primers were listed in Table 2-2. 
The standard PCR reaction was performed in the Perkin Elmer DNA thermal cycler 
Model 480 or 9600 (Perkin Elmer, USA). For a 25-µl reaction, it contained 1 µg of DNA 
template, 3 µl 25 mM MgCl2; 0.5 µl of 10 mM dNTP, 0.5 µl of each primer (10 µm ), 0.1 
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µl Taq polymerase (Promega), 2.5 µl of 10× PCR buffer (50 mM KCl; 1×10 mM Tris-
HCl, pH 9.0; 0.1% Triton X-100) and nuclease-free ddH2O. The setting for a routine 
genotyping PCR was as follows: initially denaturation at 95 °C for 3 min, followed by 35 
cycles of 95 °C 30s denaturation, 62 °C 1 min annealing and 72 °C 1 min extending, and 
final extension at 72 °C for 5 min. The PCR products were analyzed on 1% agarose gel 
with 0.5 µg/ml ethidium bromide in 1×TAE buffer. The gel was run at 100V for 10 min, 
and then visualized on 312 nm UV (Model TF-35M UV transilluminator Villber Lourmat, 
France) and photographed with Unvitech Gel Document system (Uvitech Co.). 
 
 
2.4 Histology Analysis 
2.4.1 Sample Fixation and Paraffin Embedding 
The fish with interested lesions were collected for histology analysis. The whole fish was 
fixed in 10 % neutral buffered formalin solution (Sigma, #HT5012). To ensure complete 
and thoroughly fixation, the fish was flushed with formalin several times. Fish was put in 
cassette individually, and labeled with age and transgenic background. The sample 
should not be thicker than 5 mm for complete fixation. If the fish was longer than 1 cm, 
the tail part would be cut off and then fixed together. The cassettes with fish samples 
were immersed into formalin for 5 days on shaker. After fixation, the fish samples were 
decalcified in decalcification agent (0.5 M EDTA) for 2 days. Next the fish was washed 
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with 70 % ethanol and balanced with a series of ethanol solutions with different 
concentration (70%, 80%, 95% and 100%) for dehydration. The samples should be 
balanced in each ethanol concentration for at least 2 hrs on a shaker and balance in 100% 
ethanol should have a longer duration and at least two changes of fresh ethanol to ensure 
a complete dehydration. Then the fish samples were balanced in Histoclear (Histo-
Clear®, Fisher Scientific, Pittsburgh, PA, #HIS-010-010S) with at least two changes and 
each for 3 hours. Finally, the samples were immersed in melted paraffin to replace 
Histoclear with totally at least 6 hours incubation and at least two changes of fresh 
paraffin. The samples were then embedded in paraffin blocks. For long time storage these 
paraffin embedded samples should be stored in 4 °C fridge.  
2.4.2 Histology Section 
The section block was first oriented to a position so that the fish back was parallel to the 
blade. The paraffin block was then trimmed to remove the extra paraffin to expose the 
sample. The block surface was soaked in 5 % family laundry fabric soften solution on ice 
for 1-2 hr to improve the section performance. Sectioning was performed using a Leica 
microtome, and all the samples were cut sagittally at the thickness of 4 µm. The sections 
were collected on charged SuperFrost Plus microscope slides (Fisher Scientific, #12-550-
15). Usually, the control fish and tumor fish were placed parallel on the same slide to 
narrow the differences in staining process. Slides were dried on 42 °C hotplate overnight, 
and stored in 4 °C fridge. 
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2.4.3 Hematoxylin & Eosin Staining 
Before staining, the sections brought from 4 °C fridge were firstly dried on a hotplate of 
42 °C for 1 hr. The slides were dewaxed in Histoclear and rehydrated in a series of 
ethanol solutions with different concentrations of 100%, 90%, 70% and 50%. After two 
washes in ddH2O, the slides were stained with filtered Hematoxylin (Sigma, #51275) 
solution in dark for 20 min and the color of Hematoxylin was differentiated in running 
tap water wash. Next the slides were dehydrated with 50%, 70% and 90% ethanol in 
sequence and then were stained with Eosin (Sigma, #HT110232) in dark for 10 min. 
Finally the slides were dehydrated and re-waxed with absolute ethanol and Histoclear, 
and mounted in DePeX medium (BDH Laboratory Suppliers, Poole, U.K. #361252B). 
After air dry in a fume hood for overnight, the paraffin section samples were ready for 
observation. Usually, the stained samples were stored in dark at room temperature. 
2.4.4 Slides Observation and Diagnoses 
Currently, there are no histological pathology standards for diagnosing zebrafish liver 
tumors, but it has been shown that carcinogen treated zebrafish could develop liver tumor 
highly resemble the human ones(Lam, Wu et al. 2006). Therefore, the zebrafish liver 
tumors were graded based on the criteria developed for classifying human and rodent 
liver neoplasm as tabulated in Table 2.3 (summarized from Altas of tumor pathology, 
Tumors of the liver and intrahepatic bile ducts(Rosai 2001))
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Table 2-3. Liver Neoplasm Lesion Classification (Human)(Rosai 2001) 







 Dark red organ with 
four lobes in human. 
 From 10-12 cells to 1-2 
mm. 
 Pale or grey or 
invisible. 
 Vary in size. 
 Round lesion with clear border.
 Usually elevated above liver 
surface. 
 Vary in size. 
 A solitary bump with 
regular and sharp border. 
 Vary in size. 
 The surface and 
boundary is irregular. 
Cytoplasm 
 Polyhedral cells with a 
granular eosinophilic 
cytoplasm. 
 Cells are vary in size 
 More basophilic or 
eosinophilic than 
normal. 
 Cells vary in size. 
 More basophilic or eosinophilic 
than normal. 
 Cells vary in size. 
 More basophilic or 
eosinophilic than normal. 
 May have increased 
vacuoles. 
 Cells vary in size. 




 Usually have one 
basophilic nucleus 
located on the edge of 
the hepatocytes 
 Most are larger than 
normal. 
 May have prominent 
nucleoli. 
 No mitosis. 
 Most are larger than normal 
 May have prominent nucleoli. 
 Mitosis may be observed. 
 May be larger than normal 
or maintain normal 
morphology 
 Uniform in the whole 
tumor. 
 Mitosis is rare.
 Most nuclei are 
pleomorphic and have 
distinct enlarged 
nucleoli. 




 Organized in cell-thick 
plates.  
 The sinusoid between 
the hepatocytes plates 
are usually lined by 
epithelial cells. 
 Maintain normal 
hepatocytes cell plates 
structure. 
 Maintain hepatocytes cell 
plates.  
 The sinusoid may be either 
more narrow or wider than 
normal. 
 Discontinuous with 
surrounding tissue. 
 Most lost normal hepatic 
plates and organized in 
cord or sheets instead 
 Loss of normal hepatic 
plates. 
 Malignant hepatocytes 
are organized in to 






 Hepatocytes form the 
majority bulk of liver. 
 No clear boundary. 
 But may not 
continuous with 
adjacent region. 
 Usually has a clear boundary. 
 Compress is absent. 
 Have a sharp boundary. 
 Always compress 
surrounding normal 
tissues. 
 No distinct border. 
 Invading the normal 




2.4.5 Immunohistochemistry Staining 
The paraffin slides were dewaxed and rehydrated in the method mentioned in Section 
2.4.3. To break the methylene bridges and to retrieve the antigen, the slides were firstly 
treated with the PH 6.0 buffer [10 mM sodium citrate in milliQ water or DAKO citrate 
buffer (pH, 6.0), dilute to 1X] and heated in microwave. The heating process was 
carefully monitored to prevent over boil and evaporation. Usually for up to 10 slides 
processed according to Section 2.4.1 and for the PCNA/E-cadherin/β-catenin antigens, 
about 10 to 15 min heating was suitable.  
The slides were then cooled down naturally and slowly at room temperature. Next, the 
slides were washed with PBST (3.2 mM Na2HPO4, 0.5 mM KH2PO4, 1.3 mM KCl, 135 
mM NaCl, 0.05% Tween® 20, pH 7.4) thoroughly. After inhibiting endogenous 
peroxidase activity by 10 min 3% H2O2 incubation at room temperature, the sections 
were then blocked with 5% goat serum in PBST at room temperature for 3 hrs. Next the 
slides were incubated with primary antibody in humidified chamber overnight at 4 °C. 
The primary antibodies used in this study were as follows: PCNA (AnaSpec Inc. #55421), 
β-catenin (#ab32572) and E-cadherin (#ab1416) from Abcam (Cambridge, United 
Kingdom).  Based on the sensitivity of each antibody, they were diluted in 5 % goat 
serum (in PBST) in different times: β-catenin and E-cadherin 1:200 dilution, PCNA 
1:500 dilution. After that the slides were washed with PBST and incubated with 
appropriate secondary antibody from Dako Kit set (DAKO, Denmark, #346811) at room 
temperature for 1 hour. The secondary antibody were conjugated with HRP (horseradish 
peroxidase), and its color could be visualized by the Liquid DAB & Substrate 
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Chromogen system (DAKO, Denmark, #346811) according to the manufacturer’s 
guidelines. The color development was carefully monitored under microscope to avoid 
over-staining. After washing with PBST, the samples were conterstained with 
hematocylin. Finally, the sections were dehydrated and mounted in the way described in 
2.3.4. The IHC stained section samples were stored in dark at room temperature. 
2.4.6 TUNEL Staining 
The paraffin slides were dewaxed and rehydrated according to the method mentioned in 
2.4.3. After 50% ethanol balance, the sections were washed twice with 5 min PBS 
immersing. TUNEL assay was conducted by ApopTag® Plus In Situ Apoptosis 
Fluorescein Detection Kit (Chemicon® international, #S7111). After the 15 min treatment 
with 20 µg/ml Proteinase K (in PBS) at room temperature and thoroughly wash, the 
sections were treated with TDT enzyme and incubated with AP conjugated Anti-DIG 
according to the protocol. Next the slides were washed with PBS and balanced in pH 9.5 
buffer (0.1M Tris-HCl/50mM Mgcl2/ 10mM Nacl/0.1% Tween 20) at room temperature. 
Finally the signals colors were developed using NBT (4.5 µl)/BCIP (3.5 µl) in 1 ml pH 
9.5 buffer. The color development was carefully monitored under microscope to avoid 
overstain. When apoptosis in the intestine (positive control) of the same section was 
clearly seen, the color development was stopped with PBS washing. The slides were also 
conterstained with 5 µg/ml DAPI (4’, 6-Diamidine-2’-phenylindole dihydrochloride) at 
room temperature for 10 min. After wash with PBS, the slides were mounted with 
fluoresave medium and air dried at room temperature in dark for 2 hours. Usually the 
observation and photo taking were done in one week. 
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2.5 Cryosection and GFP Observation 
2.5.1 Tissue Fiction & Cryosection 
The fresh liver samples were fixed overnight in 4 % PFA (4 g paraformaldehyde per 100 
ml PBS) at 4 °C on a shaker. The samples were then washed thoroughly with PBS and 
then balanced in 30% sucrose PBS solution overnight at 4 °C on a shaker. Next, the liver 
samples were embedded in tissue freezing medium cryostat (Reichert-Jung, Germany) on 
prechilled sample holders. The whole sample holder was placed above liquid hydrogen to 
let the cryostat medium froze. The frozen blocks were equilibrated at -25 °C for 2 hours 
in the chamber of microtome (Leica CM 3050S) before section. Usually, the samples 
were cut at a thickness of 8 µm. The sections were collected on Superfrost Plus slides 
(Fisher, USA) and air dried in dark at 42 °C for about 30 min. The sections were then 
ready for further procedures or storage at -20 °C for weeks.  
2.5.2 Confocal Microscope Observation & Imaging Processing 
To observe nuclei, the slides were stained with DAPI according to the method in Section 
2.4.5. The slides were immersed in a drop of PBS and sealed with coverslip before 
confocal microscope observation. Zeiss LSM 5 Exciter upright confocal (Carl Zeiss Inc., 
Germany) were adopted for observation. 488 nm excitation was used for GFP 
observation while 405 nm excitation for DAPI. Raw images were taken with 100× 
objective using LSM 510 Software (Carl Zeiss Inc., Germany). Image processing were 
done with ImageJ (Java-based image processing program, NIH, U.S.). 
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2.6 Statistic Methods 
2.6.1 Genotyping and Goodness of Fit Test 
The null hypothesis (H0) was that the transgenic Effector fish only carried a single site 
insertion of the exogenous gene in the genome, and the transgene passed to the next 
generation randomly and followed the law of Mendelian inheritance in outcrossing. If H0 
was correct, the Effector offspring and non-Effector offspring number should be equal, 
and the statistic χ2 follow the chi-squared distribution. Then the test of goodness of fit 
was performed in Excel to determine whether to reject the null hypothesis or not. 
2.6.2 Survival Curve (Kaplan-Meier Curve) Calculate and Log Rank Test 
The death of zebrafish larvae of each test group were recorded daily. The Kaplan-Meier 
survival curve was generated by Excel scatter chart based on the death record. Log-rank 
test was performed in Excel manually to compare the survival distributions of each two 
groups. If the p-value of two survival curves in log-rank test was less than 0.05, the 
survivals of the two groups were considered to be statistically and significantly different. 
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Chapter 3 Results 
3.1 Mifepristone Inducible System to Control Oncogene Expression 
3.1.1 System Design of the LexPR Mifepristone Inducible System 
To enables temporal control of transgene expression, and allow revisable expression by 
withdrawal of the chemical inducer,  the mifepristone-inducible LexPR system 
(Emelyanov and Parinov 2008) was employed in this study. According to the system 
working principles described in Section 1.5.2 and presented in Figure 3-1, two transgenic 
lines are required to generate.  
One line is the Driver line which expresses the chimeric LexPR transactivator in 
zebrafish hepatocyte specifically under the control of liver specific lfabp promoter. This 
Driver line also contains the LexOP operator which controls the expression of GFP. 
Therefore, with the administration of mifepristone, the Driver line could express GFP in 
the zebrafish liver. This GFP expressing property not only enables convenient screening 
and observation but also serves as a good marker for liver morphology.   
The other important part of this system is the Effector line which harbors the transgenic 
oncogene. The oncogene of interest is fused with a GFP tag and placed under the control 
of LexOP operator. Therefore, without the existence of LexPR operator and mifepristone, 
the oncogene of the Effector line would not express. The GFP tag fused to the transgene 
helps to trace the oncogene expression and cellular location. This line also carries a 
mCherry tag which expresses specifically in zebrafish eyes to facilitate screening.  
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Double transgenic line is generated by crossing the Driver line with the Effector line. 
This double transgenic fish possess constructs from both the Driver line and the Effector 
line. The chimeric LexPR transactivators from the Driver line construct express in 
hepatocyte. When these fish are exposed to mifepristone, the LexPR transactivator in 
hepatocyte could bind to the LexOP operator in the Effector line construct. And 





Figure 3-1. Scheme of the Mifepristone Inducible LexPR System. 
A. Schematic representation of the LexPR system design of Driver line and the Effector line. The 
Driver line expresses the LexPR transactivator in zebrafish hepatocytes under the control of lfabp 
promoter. Effector line carries the LexOP operator and the GFP fused oncogene, as well as a 
mCherry tag expressing in eyes. The whole fragments were inserted into the pBluescriptII SK(+) 
vector. 
B. Double transgenic line contains constructs from both Driver and Effector. With the presence of 
mifepristone, the chimeric LexPR transactivator expressed from the Driver construct could 










3.1.2 Mifepristone Concentration below 6 μM was Safe to Zebrafish 
Mifepristone, a synthetic steroid compound, is also a widely-used abortifacient or 
emergency contraceptive in clinic. To ensure effective utilization of mifepristone in this 
project, a general study of mifepristone toxicity in zebrafish and the LexPR system 
induction sensitivity was firstly conducted.  
The LiPan fish, a transgenic zebrafish line which specifically expresses RFP in the liver 
and GFP in the exocrine pancreas, was employed in a mifepristone toxicity test. The 
LiPan embryos from three to five pairs of parents were collected and evenly divided into 
10 groups. Unfertilized eggs were removed at 0.5 day post fertilization (dpf) and then 
treated with 0 µM (egg water), 2 µM, 4 µM, 6 µM, 8 µM, 10 µM, 30 µM, 50 µM and 70 
µM mifepristone respectively. As mifepristone was first dissolved in ethanol, a batch of 
embryos treated with 350 µl ethanol/ 100 ml egg water (the highest amount of ethanol 
used as dissolvent in the test) were used as vehicle control.  
The impacts of mifepristone treatment on LiPan embryo development were summarized 
in 100% stacked columns in Figure 3-2 B, C, D. Firstly, it showed that the amount of 
ethanol used as solvent vehicle had no impacts on embryo development. Secondly, low 
mifepristone concentration treatment, below 6 µM, could be safe to the zebrafish embryo. 
Although there might be a developmental delay and a decrease of the hatch-out rate in the 
2 µM and 4 µM mifepristone treated group at 2 dpi/2.5 dpf, the final hatch-out rate at 3 
dpi/3.5 dpi was comparable to the controls. In contrast, mifepristone concentration above 
8 µM could be harmful to the hatch-out process of zebrafish embryos and caused an 
edema rate in larvae, as indicated in Figure 3-2C. Moreover, mifepristone concentration 
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above 10 µM seems to be lethal to zebrafish embryos. Dramatically increase of the death 
rate to 80% was observed in the treatment above 10 µM since 4 dpi.  
Figure 3-3 further illustrates the development of major organs in the mifepristone 
treatment. Exploiting the merits of LiPan fish, the liver and pancreas were highlighted by 
RFP and GFP expression respectively and therefore could be observed under a 
fluorescence microscope. Embryos from the mifepristone treatment above 10 µM were 
not presented because very few larvae could hatch out. Shown in Figure 3-3, the liver and 
pancreas emerged at 3.5 dpf and 4.5 dpf respectively. Based on the view of liver shape 
and size, mifepristone concentration below 10 µM had little effects on liver and pancreas 
development, but it affected the inflation of swim bladder in the treatment above 8 µM. 
The abnormality of swim bladder may account for the high mortality mentioned in the 
previous section and also explains why the pancreas exhibited an abnormal flat shape in 
the 8 µM and 10 µM mifepristone treated groups since 4 dpi (Figure 3-3).  
The conclusion that mifepristone concentration above 8 µM might be harmful to larvae 
was also supported by the survival curve. As presented in Figure 3-4, long term treatment 
in mifepristone treatment above 8 µM was lethal to the larvae. The log-rank test also 
indicated that the survival curves of larvae in treatment above 6 µM had significant 
difference with the control larvae in fresh fish water (0 µM).  
Therefore, based on these experiments, the safety dosage of mifepristone treatment 
should be below 6 µM. As the liver bud is formed at 3 dpf, in this liver cancer project, the 





Figure 3-2. LiPan Fish Development in Mifepristone Treatment. 
0 μM (egg water) and EVC (the Ethanol Vehicle Control) were used as control. 
A. Experiment procedure and timeline. B, C, D. LiPan embryos development records at 2 dpi/2.5 
dpf, 3 dpi/3.5 dpf and 4 dpi/4.5 dpf.  
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Larvae: the healthy hatched larvae; Non-hatch: embryos that have not hatched out; Edema larvae: 
the larvae with edema; Death: died larvae and eggs. 
 
 
Figure 3-3. Organs Development in Mifepristone treated Zebrafish Larvae. 
LiPan embryos were treated with mifepristone of different concentration from 12 hpf; 
development were monitored in subsequent days and recorded by a microscope camera. Liver 
was presented by RFP, and pancreas was by GFP. Embryos of the same date (showed in one line), 
were photographed at the same magnification and with the same exposure time. 0 μM (egg water) 






Figure 3-4. LiPan Fish Survival Curves at Different Mifepristone Concentrations. 
LiPan embryos were treated with different concentrations of mifepristone from 12 hpf till 10 dpi. 
0 μM (egg water) and EVC (ethanol vehicle treatment) treated fish were used as control. Lines in 
different color represent survival curves at different mifepristone concentrations. ##, indicates 




3.1.3 Mifepristone Induction Sensitivity and Expression Kinetics 
In this mifepristone inducible LexPR system, the expression intensity of a foreign gene 
may depend on the concentration of mifepristone, because the availability of mifepristone 
molecules in solution may affect the level of dimerization of the LexPR transactivator 
and then the activation of transgenic oncogene expression. In the original paper reported 
on this LexPR inducible system (Emelyanov and Parinov 2008), it was mentioned that 
this system, controlled by an enhancer-trap promoter, could response to as low as 1 nM 
mifepristone, while 10 nM mifepristone enabled a strong expression in zebrafish larvae. 
However, the performance of this system under the lfabp promoter had not been studied 
yet. Therefore, the Driver line which carries the intact mifepristone LexPR system and 
expresses GFP in the liver under the mifepristone induction were tested in the present 
study to determine induction sensitivity and expression kinetics of this system. 
In this experiment, Driver line larvae from three to five pairs of crosses were collected, 
mixed and treated with mifepristone of different concentration (0 µM, 0.005 µM, 0.05 
µM, 0.5 µM, 5 µM) from 3 dpf. The embryos were observed and photographed at 12 hpi, 
24 hpi and 48 hpi.  
Figure 3-5 illustrated the observed GFP fluorescence in the larvae liver which were 
induced by mifepristone at different concentrations. Firstly, the images from top to 
bottom showed that GFP expression in response to mifepristone induction increased with 
the treatment duration. Larvae at 12 hpi displayed only faint GFP signals, as shown in 
Figure 3-5 A to D, but the signal increased dramatically in the following 12 hours (E to H) 
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and leveled off since 24 hpi (I to L). Secondly, it also indicated that the system was very 
sensitive to mifepristone induction. Although the signal was weak, the GFP expression 
could be observed in the induction as low as 0.005 µM mifepristone. Finally, the 
expression of the reporter gene increased with mifepristone concentration. From Figure 
3-5 E to H and from I to L, the GFP fluorescence enhanced with the mifepristone 
concentration increasing. It seemed to be saturated at 0.5 µM, as no further significant 
increase was observed in the Driver line above this concentration. 
 
Figure 3-5. GFP Expression in the Driver Line Liver in Response to Mifepristone at 
Different Concentrations.  
Driver line larvae were treated with 0.005 μM, 0.05 μM, 0.5 μM, 5 μM mifepristone from 3 dpf. 
GFP expression in Driver liver was recorded by a microscope camera. All the photos were taken 
in the same magnification and with the same exposure time. 
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3.2 Comparative Study of Zebrafish myca and mycb Tumorigenicity 
3.2.1 Zebrafish myca and mycb are Orthologs of Human MYC 
3.2.1.1 The myc Oncogene Family in Zebrafish 
Zebrafish myc family is composed of six genes, mycn, mych, and two paralogous gene 
pairs, myca and mycb, mycl1a and mycl1b. All of them are involved in development and 
especially express in high proliferating regions (Meijer, van der Sar et al. 2008). However, 
the expression of myc family in adult liver has not been comprehensively studied. 
In this project, the expression of myc family members in adult zebrafish liver was 
examined by quantitative PCR (qPCR). Wild type and Driver line zebrafish of three 
months old were sacrificed for total RNA extraction and cDNA synthesis. Quantitative 
PCR was conducted according to the methods describes in Section 2.3.3. Figure 3-6 
shows the expression of myc family in adult zebrafish livers. mycb and mych had much 
higher expression in adult liver than other myc genes. In contrast, mycn, mycl1a and 
mycl1b only had a trace expression in mature liver in both Driver and WT fish, and were 
all significant lower than mycb and mych (p < 0.05). The average expression of myca 
was higher than those of mycn, mycl1a and mycl1b, but much lower than those of mycb 
and mych in both Driver and WT fish liver (p=0.053 and p =0.060 respectively). This 
observation was also consistent with zebrafish liver RNA-Seq data generated in our 
laboratory (Li, Zheng et al. 2013). As indicated in green triangles in Figure 3-6, the 
RNA-Seq data also showed that mycb was the highest expressed myc gene in adult liver, 
and mych was the second highest while all the others had rare transcripts. No myca 
expression was detected in the RNA-Seq data, although it was detected by qPCR and it 
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was even higher than mycn, mycl1a and mycl1b. This discrepancy could be attributed to 
the relative high individual variation of myca expression in adult liver tissues.   
In summary, the endogenous myc family expression in zebrafish liver was highly diverse. 
Noticeable, the paralogous genes pairs, myca and mycb which were generated from the 
same the ancestor gene have distinct expression patterns in the liver. 
Figure 3-6. Zebrafish myc Family Gene Expression in Adult Liver. 
Livers were collected from adult WT zebrafish and Driver for qPCR and each group had four 
biological replicates. The blue and red columns represent qPCR data of WT and Driver fish 
respectively, while the green triangles are TPM (transcripts per million) based on RNA-seq data 
from wild type fish liver of an independent study(Li, Zheng et al. 2013). The error bars represent 
stand deriation. § indicates the p-value of the expression differences between myca and mycb in 
WT fish liver is 0.060. §§ indicates the p-value of the expression differences between other myc 
and mycb in the WT fish is less than 0.01. # indicates the p-value of the expression differences 
between myca and mycb in Driver fish liver is 0.053. ## indicates the p-value of the expression 
differences between other myc and mycb in the Driver fish is less than 0.01. No significant 
differences were found between WT and Driver. 
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3.2.1.2 myca and mycb Have Many Differences in Sequence Comparison and Cladogram 
The WGD (whole genome duplication) doubled the genome size of teleosts and provided 
abundant materials for neofunctionalization and subfunctionalization of genes and 
therefore promoted the evolution (Jaillon, Aury et al. 2004). There are some possible 
consequences of the paralogous genes after duplication: one gene possessed the whole 
function of the ancestor and the other gradually lost function and become pseudogene; 
subfunctionalization in which both genes were functional and complement each orther for 
the function of the ancestor; as well as neofunctionalization, in which one gene retained 
the function of the ancestor while the other evolved new functions. Both zebrafish myca 
and mycb are orthologous counterparts of the human MYC. The distinct expression 
pattern of these paralogous myca and mycb in zebrafish livers raised a possibility that 
these two genes might have different functions in normal physiology as well as in 
oncogenicities. 
As described in Section 1.2.1.1, the transcription activating ability of Myc proteins are 
tightly related with its function and therefore all vertebrate Myc proteins have a 
conserved scheme in structure. Any changes in the sequence may have an effect on the 
conserved protein structure and then affect Myc function (Meyer and Penn 2008). In 
order to further investigate the differences between zebrafish Myca and Mycb, a study 
about their divergence in structure were performed.  
As shown in Figure 3-7, although the TAD domain is the most diverse parts among fish 
and mammalian Myc proteins, the MB motifs within it are highly conserved. All the four 
MB motifs are identical between zebrafish Myca and Mycb. Both MB I and MB II motifs 
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are even completely identical among all four species, while MB III and MB IV only have 
one amino acid difference between zebrafish and mammals. The conservation of MB 
motif is in agreement with the previous finding that mutation or deletion of those 
structures, especially MBI and MBII will cause a loss of MYC function (Meyer and Penn 
2008).   
Besides the MB motifs, the bHLH domain which serves for DNA binding is the most 
conserved structure among fish, mouse and human. However, although the leucine 
residues for dimerization are conserved from fish to mammal (labeled in red rectangular 
in Figure 3-7 and referred to Section 4.2.1), the whole LZ domain between zebrafish 
Myca and Mycb is highly diverse. The divergence of sequence in this domain between 
the paralogs is even larger than that between human and mouse. The phylogenic tree 
based on LZ alignment also supported this finding (Figure 3-8). By alignment of other 
domains including TAD, bHLH and even the complete Myc sequences, these two 
zebrafish Myc protein were clustered together in one branch in the phylogenic tree. The 
estimated evolutionary distance showed that the genetic distance of the LZ domain 
between the zebrafish Myca and Mycb was about 3.074×10-2, which was almost twice of 
the evolutionary distance between human and mouse MYC/Myc LZ domains (1.562×10-
2). Especially, we noticed a transition of residue from Ser to Cys between Myca and 
Mycb (as labeled in green rectangles in Figure 3-7) which might affect the 
phosphorylation and disulfide bond formation. These divergences in sequences, as well 
as the great difference in expression, prompted us that the function of the two zebrafish 




Figure 3-7. Zebrafish, Human and Mouse Myc Protein Sequence Comparison. 
Zebrafish Myca, Mycb, mouse Myc and human MYC protein sequences were aligned by 
ClustalOmega. All the four sequences were compared to the consensus sequence, which is at the 
bottom of each line; similarity was presented in percentage identity (PID).  
The black columns summarize the conservation of each residue. Red rectangles label the 
conserved leucine residues. Green rectangles show the noticeable residue changes from S to C 
between Myca and Mycb. The important domains and motifs are labeled in colorful squares 
above the sequence. NLS: Nucleus Localization Sequence; bHLH: basic Helix-Loop-Helix 




Figure 3-8. Phylogenic Analysis of Zebrafish, Human and Mouse Myc Protein Sequences. 
Phylogenic trees of zebrafish Myca, Mycb, mouse Myc and human MYC protein sequences and 
their sub-domains were generated by ClustalOmega. The top one is whole sequence clustering, 
followed by domain clustering. The number behind sequence name was estimated evolutionary 










3.2.2 mycAG and mycBG Transgene Oncogenicity Comparison in Zebrafish 
To evaluate the function of Myca and Mycb, we employed the mifepristone-inducible 
transgenic system (Section 3.1) and generated mycAG and mycBG Effector lines which 
carry GFP fused Myca or Mycb respectively. These Effector lines were then crossed with 
the Driver line to generate the mycAG and mycBG transgenic fish, respectively. In order 
to distinguish from the endogenous myca and mycb, “mycAG” and “mycBG” were used 
to indicate these GFP fused exogenous myca and mycb, in which “G” stands for the GFP 
tag.  
Controlled by lfabp promoter, the mycAG and mycBG transgenic lines could express the 
exogenous genes in zebrafish liver specifically with the induction of mifepristone. The 
GFP tags attached to the C-terminal of the myca and mycb proteins enabled us to trace 
the expression and cellular location of the transgenic proteins.  
3.2.2.1 Transgenic mycAG and mycBG Fish Genotyping 
Firstly, all the F1 fish of mycAG and mycBG Effector lines were genotyped according to 
the method described in Section 2.1.4. If the Effector fish harbor only a single insertion 
of the mycAG or mycBG transgene in the genome, the outcross should follow the law of 
Mendelian inheritance. Therefore, half of the outcross offsprings should be Effector. As 
indicated in Table 3-1 and Table 3-2, the statistical analysis showed that, the mycBG 
Effector line fit very well with the Medelian inheritance, and the segregation ratios were 
around 0.5 which indicated that there was only one transgenic insertion site in the 
mycBG Effector genome. However, the segregation ratio of mycAG Effector fish 
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outcross was around 0.75. Therefore, at the significance level of 0.05, at least two segreg  









3.2.2.2 Transgenic mycAG and mycBG Expression in Zebrafish Hepatocytes 
The expression of mycAG and mycBG transgene in response to mifepristone induction 
was determined by qPCR. Embryos from mycAG F1 transgenic fish incrosses and 
mycBG F1 transgenic fish incrosses were collected, mixed and treated with mifepristone 
of different concentrations (0.5 µM, 2 µM and 4 µM) from 3 dpf. At 5 dpi, larvae from 
each treatment group were collected and homogenated for RNA extraction and qPCR. As 
shown in Figure 3-9, the expression of mycAG transgene was higher than mycBG. 
Moreover, the mycAG and mycBG transgene expression increased slightly with the 
increase of mifepristone concentration, but it appeared to reach a plateau with 2 µM and 
no further increase was observed with higher concentrations. 
Oncogenicity of myc gene usually occurred when its expression is consistently above a 
threshold (Meyer and Penn 2008). Therefore, the exogenous mycAG and mycBG 
transgene expression were compared with their endogenous counterpart. To evaluate the 
possible endogenous myc expression during early development, fish from mycAG and 
mycBG transgenic lines were induced from 1 mpf with 2 μM mifepristone, and sacrificed 
at 2 mpf/1 mpi. RNA from fish liver tissue was collected for qPCR. As shown in Figure 
3-10, we found that firstly, the primer sets could distinguish endogenous myc and 
transgenic myc very well, as no mycAG/mycBG transgene expression were detected in 
the livers of Driver control. Moreover, the exogenous mycAG and mycBG transgenes’ 
expression was much higher than endogenous myca and mycb in these transgenic fish 
livers. Finally, consistent with the previous results, the mycAG transgene expression was 




Figure 3-9. Transgenic mycAG and mycBG Expressions in Zebrafish Liver in Response to 
the Induction of Mifepristone of Different Concentrations. 
mycAG transgenic line and mycBG transgenic line larvae were treated with 0.5 μM, 2 μM, 4 μM 
mifepristone from 3 dpf. Larvae were collected at 5 dpi for RNA extraction. Transgenic mycAG 
and mycBG expression was measured by qPCR. All the expressions were compared with the 
average mycAG transgene expression in 0.5 μM mifepristone treatment, which is set as 1. The 
error bars represent stand deriation. The p-value of the expression differences between mycAG 








Figure 3-10. Expression Comparison of the Endogenous myca and mycb with Transgenic 
mycAG and mycBG. 
mycAG transgenic line and mycBG transgenic line fish were treated with 2 μM mifepristone 
from 1 mpf. Fish livers were collected at 1 mpi for RNA extraction. Each group has three to four 
biological replicates, except for mycAG transgenic fish, which had two. Transgenic mycAG gene 
and mycBG gene, endogenous myca and mycb expression was measured by qPCR. All the 
expressions were compared with the endogenous myca expression in Driver liver, which is set as 
1. The error bars represent stand deriation. The p-value of expression comparison was 
summarized in the table below the graph. The first two lines were transgenic and endogenous 
gene expression compared within the same transgenic fish, as the line name indicated in ( ); the 
last two lines were the expression of the same gene compared cross transgenic lines and the 
transgenic line name were indicated in ( ).  
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3.2.2.3 Transgenic mycAG and mycBG Proteins Localized in Hepatocytes Nucleus 
As transcription factors, functional myc proteins are supposed to be localized in cell 
nucleus. All the transgenic proteins have GFP tags at their C-terminal, and therefore, the 
cellular localization of mycAG and mycBG proteins could be traced easily. Moreover, 
the GFP signal can be preserved by cryo-section and observed for cellular localization. 
Larvae from mycAG and mycBG transgenic lines were induced with 2 μM mifepristone 
since 1 mpf and  fresh liver were collected at 1 mpi for cryo-sectioning. The slides were 
stained with DAPI, which visualized nuclei with blue fluorescence. Wild-type zebrafish 
livers were used as a negative control for the possible auto-fluorescence of hepatocytes. 
Livers of Driver fish were used to demonstrate the distribution pattern of empty GFP tags 
without myc fusion. 
The results are summarized in Figure 3-11. In the first row of pictures (A to C), no GFP 
or auto-fluorescence signal was observed in the wild type fish hepatocytes. The sections 
from the Driver control in the second row of pictures (D to F) show empty GFP tags 
uniformly distributed in hepatocytes. However, in sharp comparison, nucleus-localized 
GFP signal was clearly presented in the mycAG transgenic fish hepatocytes. Interestingly, 
the nuclei of the mycAG transgene expressing hepatocytes were also significantly larger 
than the wild type and Driver control, which could be a sign of pathologic changes due to 
mycAG transgene over expression. However, nucleus-localized GFP signal was not 
presented in all mycBG expressing hepatocytes. Interestingly, the mycBG expressing 
hepatocytes with nucleus localized GFP also had a significantly enlarged nucleus which 
was similar to the observation in mycAG transgene expressing hepatocytes, while the 
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cells without nucleus-localized GFP had normal nucleus similar to the ones in the wild 
type and Driver control hepatocytes. The above results indicated that the transgenic 
mycAG protein was clearly localized in nucleus and could be oncogenic. The uneven 
cellular distribution of mycBG protein was perhaps due to the uneven expression in 
















Figure 3-11. Subcellular Localization of Transgenic mycAG and mycBG Protein. 
Adult induced with 2 μM mifepristone from 1 mpf. Liver tissues from mycAG line, mycBG line, 
Driver line and wild type (no treatment) fish were collected separately at 1 mpi for cryosection. 
The GFP signal was recorded by confocal microscope GFP channel. Nucleus were stained by 
DAPI and recorded in Blue channel. Wild type zebrafish liver was used as negative control. 
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3.2.2.4 Comparison of mycAG and mycBG Oncogenicity at Zebrafish Larvae Stage 
The previous data indicated some differences and similarities between zebrafish Myca 
and Mycb, but their oncogenicity was still unknown. The merits of small size and 
transparent trunk at larvae stage make zebrafish fry a good experimental material for 
observing tumor progression. Take these advantages, the oncogenicity of mycAG and 
mycBG transgenes was compared in vivo in zebrafish larvae. F2 Embryos from mycAG 
and mycBG transgenic fish incross were maintained in normal egg water till 3 dpf, and 
the expression of mycAG and mycBG transgenes was induced by mifepristone of 
different concentration (0.005 μM, 0.05 μM, 0.5 μM, 2 μM, 4 μM). The liver morphology 
was manifested by the GFP signal, and the liver growth was observed and recorded by a 
microscope camera at 5 dpi. The results are summarized in Figure 3-12. 
As shown in Figure 3-12, the expression of mycAG and mycBG transgenes, as 
manifested by GFP expression, became saturated at 2 μM, and no obvious further 
increase was observed with higher mifepristone concentration induction. The over 
expression of the exogenous mycAG transgene caused significant overgrowth of liver, 
and this could be observed with induction by mifepristone at as low as 0.005 μM. 
However, in the gross observation, the GFP signal in mycBG line was also not as bright 
as that in mycAG transgenic line, which was in consistent with the previous qPCR data. 
Compared to the Driver control fish, it also seemed that the mycBG expression had no 
notable effect on liver growth.  
The survival rate of the larvae fish treated with 2 μM mifepristone was followed till 10 
dpi and the survival curve was plotted in Figure 3-13. It was apparent that mycAG 
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transgene expression increases the mortality of zebrafish larvae. The abnormality of liver 
might affect the vitality of the larvae, as most of mycAG expressing fry tended to sink at 
the bottom of the tanks. The same effect was also observed in some mycBG fish fry, and 
the survival rate of this line also decreased compared to the Driver controls. 
These results indicated that mycAG transgene expression might be involved in liver 
hyperplasia. However, the expression of mycBG transgene was not as high as that of 
mycAG, and no significant growth promote effect were observed in larvae treatment, but 
the survival rate of mycBG transgenic larvae significantly decreased during the treatment, 
indicating that in a longer expression period in mycBG transgenic fish may be required 




Figure 3-12. Effect of mycAG and mycBG Expression in Zebrafish Fry.  
Zebrafish larvae from mycAG line and mycBG line were induced with mifepristone of different 
concentrations from 3 dpf and photographed at 5 dpi. All the photos were taken in the same 
magnification and with the same exposure time. A. The livers were illustrated with GFP signal. 
mycAG and mycBG transgenic fish have both GFP signal in liver and mCherry in eyes which 
was so strong that can be detected under GFP channel. B. the liver size of embryos in treatment 
was measured according to the method in Section 2.1.7. The error bars represent stand deriation. 
## and #, indicate the liver size difference when compared with the Driver in the same 
concentration treatment is significant at the p-value level of 0.01 and 0.05 respectively. §§ 
indicate the liver size difference when compared with the mycBG in the same concentration 




Figure 3-13. mycAG and mycBG Larvae Survival Curve Comparison. 
Zebrafish larvae from mycAG transgenic line and mycBG transgenic line were treated with 2 μM 
mifepristone and their survival was followed daily till 10 dpi. Driver line embryos were used as 
control. Lines of different color in the figure represented the survival curve of different transgenic 
fish.  ##, indicates survival difference when compared to Driver is significant at the p-value level 
of 0.01 in log-rank test. §§, indicates survival difference when compared to Driver is significant 











3.2.2.5 mycAG and mycBG Oncogenicity Comparison in Adult Zebrafish 
Although zebrafish larvae are small and transparent and suitable for preliminary 
oncogenic study, this platform has some drawbacks. For example, the larvae with 
mycAG transgene expression had less motility than control which might directly affect 
feeding and cause death rather than the liver tumor growth. The organs in zebrafish 
larvae are so small that it is difficult to collect enough tissue samples for further analysis. 
Therefore, in order to have deep understanding of myca and mycb oncogenicity in long 
time induction, the mycAG line and mycBG line zebrafish were induced from 1 mpf.  
Firstly, to examine the tumor development at different oncogene expression level, 
zebrafish from different transgenic lines were induced with mifepristone of different 
concentrations (0.005 μM, 0.5 μM, 4 μM). As adult zebrafish were not transparent, the 
fish were sacrificed and dissected at 2 mpi to examine tumor growth. The morphologies 
of different groups were recorded by camera and dissection microscope. Firstly, the 
expression of the transgenic oncogenes increased with mifepristone concentrations, as 
indicated by GFP brightness in Figure 3-14. Liver over growth was observed in both lines 
even at a weak expression at 0.005 μM inductions, compared to the Driver control. The 
body length of mycAG transgenic line was also significantly smaller than the Driver 
controls. These findings indicated that both mycAG and mycBG transgenes were 
oncogenic. Also, the liver of the mycAG transgenic fish was significantly larger than the 
mycBG transgenic line, which might be due to the higher expression of mycAG 
transgene than mycBG. Finally, the liver size of both lines was increased with the 
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Figure 3-14 Gross Observation of Tumors in mycAG Fish and mycBG Fish. 
1 mpf fish from mycAG line and mycBG line were induced with mifepristone of different concentration and photographed at 2 mpi. The first row  
shows the gross observation of a group of fish from each treatment. Then fish were dissected to reveal the liver, and were recorded by the camera 
of microscope with the same exposure time. The livers were illustrated with GFP signal.  
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In human clinic study, gross anatomy plays little role in tumor classification; tumors were mainly 
diagnosed and classified by histology examination, which is a golden standard technique to study 
the microscopic anatomical changes of cells. To visualize the particular structures of interests in 
the transparent paraffin embedded tissue sections in light microscope examination, H&E staining 
was performed on the slides according to Section 2.4.3. As currently there are no tumor 
diagnoses standards for zebrafish, the fish tumors were classified according to the human 
standards which have been summarized in Table 2-3. 
The fish of mycAG and mycBG transgenic line were induced with mifepristone from 1 mpf and 
sacrificed for histology study at 2 mpi. The H&E staining results are presented in Figure 3-15. 
The Driver line with mifepristone treatment and wild type (WT) fish without mifepristone 
treatment were used as controls. As can be seen from the figures, the hepatocytes in both Driver 
and WT controls were polyhedral and organized in cell plates. These hepatocytes had 
eosinophilic cytoplasm and basophilic nuclei. Blood vessels and blood cells scattered among 
liver tissues. These observations in the Driver fish liver met the criteria of normal livers and 
there was no significant abnormality compared with the WT fish liver. Therefore, the treatment 
with mifepristone and expression of GFP has no effect on the hepatocytes morphology, and 
Driver fish could be a proper control in this study. 
In contrast, the mycAG transgene expressing fish liver distinguished itself from normal firstly 
through the basophilic cytoplasm and eosinophilic nucleoli. Moreover, the nucleus was 
significantly larger than normal hepatocytes and located in the center of the cells. The nucleus 
had a “bull-eye” appearance, in which the eosinophilic nucleoli were enlarged and located in the 
nucleus center. Mitosis was rare, but had been observed in some samples. Nucleus pleomorphics 
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increased with the mifepristone concentration. As shown in Figure 3-15, the eosinophilic bull-
eye like nucleus evenly distributed in the 0.005 μM treated mycAG transgenic fish (n=2) liver 
and was organized in two cell-thick plates; however, mycAG transgenic fish treated with 0.5 μM 
mifepristone (n=2), although cell plates was still distinguishable, the cell density increased and 
nucleus with more diverse morphology emerged; finally in the highest expression induction 
group (4 μM, n=3), cellular density was further increased and the sinusoid was compressed by 
the crowded hepatocytes. However, no invasion was observed in the samples at this stage. 
On the other hand, in mycBG fish, the low mifepristone induced group (0.005 μM, n=2) still had 
eosinophilic cytoplasm like the control fish. Although the nucleuses were still basophilic, the 
nucleoli were significantly more prominent than normal. The cell organization and nucleus 
morphology were similar to the control. But increased mitosis was observed in this group, as 
indicated by the arrows. The cell density and nucleus abnormality increased with the 
mifepristone concentration. The mycBG fish in 4 μM mifepristone induction (n=6) also have 
“bull eye” nucleus which are similar to the mycAG transgenic fish.  
Based on the liver neoplasm classification in Table 2-3, the mycBG fish induced with 4 μM as 
well as the mycAG transgenic fish with 0.005 μM might be at hyperplasia stage. mycAG 
transgenic fish with higher concentration mifepristone induction seemed in a stage transferring 
from hyperplasia to adenoma. As tumor progression in the mycAG transgenic line was faster and 
more serious than the mycBG line, it provides a more promising platform for zebrafish liver 





Figure 3-15. Histological Alterations in mycAG fish and mycBG Zebrafish Liver. 
1 mpf fish from mycAG line and mycBG line were induced with mifepristone of different 
concentrations and sacrificed at 2 mpi. The entire fish were collected for histology study. The 
slides with fish liver samples were stained with H&E, and then observed and recorded under light 
microscope. “HA” is short for “Hepatocellular Adenoma”. 
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3.3 Liver Tumor Progression in the Transgenic mycAG Fish 
3.3.1 Liver Tumor Progression in mycAG Transgenic Fish 
3.3.1.1 Both Proliferation and Apoptosis were Observed in mycAG Fish Tumor 
Development 
The tumor progression in mycAG transgenic fish was further investigated. Only one 
mycAG Effector line were used in this study. The Effector fish were crossed with Driver 
fish to generate F0 transgenic mycAG fish which were maintained by incrossing 
thereafter. Progeny from F1 onwards which are a mixture of heterozygous and 
homozygous were used for tumor study.  
In order to study the progression of the tumors, a new batch of double transgenic mycAG 
fish was induced with 2 μM mifepristone from 1 mpf. Fish were sacrificed every 10 days 
for sample collection. As shown in Figure 3-16, although the liver size was still 
comparable with control, the cellular transformation emerged in the 10 dpi samples. 
Basophilic hepatocytes with distinct eosinophilic nucleus scattered among normal-like 
hepatocytes. At this stage, hepatocytes still had the organization of cell-thick plates, as it 
was in the control liver. However, 10 more days of induction (20 dpi) transformed all the 
hepatocytes into basophilic bull-eye like tumor cells. In these 20 dpi samples, the cell 
density increased and the cell-plate structure was distorted, as indicated in Figure 3-16. 
The sinusoids were either compressed by the increased hepatocytes to form a compact 
tumor type (Figure 3-16 K) or dilated to form the pseudoglandular tumor (Figure 3-16 L). 
In the mycAG transgenic fish, significant enlargement of liver was observed in 100% of 
the transgenic fish at 1 mpi. Both types of tumors were observed in early stage induction, 
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but the pseudoglandular type was the majority at 1 mpi, and then the compact type tumor 
was increased and was more commonly observed at 2 mpi.  
 
Figure 3-16. Tumor Progression in mycAG Transgenic Zebrafish Liver. 
A. Schematic representation of experimental procedure. 1 mpf mycAG transgenic fish were 
induced with 2 μM mifepristone. The fish samples were collected every 10 days thereafter till 30 
dpi. B to E: gross observation recorded by a camera dissection microscope. F to I: GFP 
expression in the liver. J to M: The paraffin sections were stained by H&E to show cellular 







In consistent with the increase of cell density, PCNA (Proliferating Cell Nuclear Antigen) 
staining indicated an increase of proliferation in the mycAG transgene expressing fish 
liver. PCNA is a protein expressed and located in the nucleus of cells during proliferation. 
Shown in Figure 3-17 A to D, only scattered proliferation was presented in the control 
fish liver. In contrast, it existed in all the mycAG transgene expressing hepatocytes and 
its staining color increased with the mycAG transgene expression, indicating the increase 
of proliferation during the mycAG transgenic fish induction period. 
The overgrowth of tumor does not only rely on the deregulated proliferation; apoptosis 
also serves as a barrier in tumor progression, as evading apoptosis is a key characteristic 
of tumor (Hanahan and Weinberg 2011). TUNEL (Terminal deoxynucleotidyl transferase 
dUTP Nick End Labeling) assay is widely used to detect apoptosis. Apoptosis in mycAG 
transgenic fish caused tumor progression was checked according to the method described 
in Section 2.4.6.  
The TUNEL assay data are presented in Figure 3-17 E to H. In contrast to rare apoptotic 
cells in Driver control, the observed apoptosis signal in mycAG transgene expressing 
hepatocytes was strong and enhanced with the induction period. This finding may be 
conflict with the tumor progression theory, in which a successfully formed tumor has 
escaped the control of apoptosis. However, observing apoptosis in mycAG transgenic 
fish liver tumor was not surprising. Some early research had revealed the fact that Myc 
does not only active proliferation signal but also induce apoptosis through the pathways 
of p53, mitochondria and death receptors(Thompson 1998; Nilsson and Cleveland 2003; 
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Hoffman and Liebermann 2008). This property of myc serves as a safe guard and 
impedes the deregulated myc promoting tumor progression. In these mycAG transgenic 
fish liver tumors, liver still could undergo overgrowth with strong apoptosis. It seems that 
the proliferation promoted by mycAG transgene has surpassed its induced apoptosis. 
Figure 3-17. Proliferation and Apoptosis in mycAG Transgenic Zebrafish Liver Tumor 
Progression.  
1 mpf mycAG transgenic fish were induced with 2 μM mifepristone. The fish samples 
were collected every 10 days thereafter till 30 dpi. A-D: The PCNA staining indicates the 
proliferation in hepatocytes. E-H: the TUNEL staining reveals the apoptosis. I: Column 
represent of the proliferation and apoptosis in each group, each group has 2 to 4 
biological replicates. The error bars represent stand deriation. ＃＃, indicates the 
proliferation differences when compared to Driver at 30 dpi is significant at the p-value 
level of 0.01. § and §§, indicate the apoptosis differences when compared to Driver at 30 
dpi is significant at the p-value level of 0.05 and 0.01respectively.  
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3.3.1.2 Diverse Phenotypes Emerged since 2 mpi 
Compared to the relatively uniform phenotypes in mycAG transgenic fish in the first two 
months of mifepristone induction, diverse tumor phenotypes emerged in mycAG 
transgenic fish from 2 mpi. One batch of 6 mpi (7 mpf) mycAG transgenic fish were 
sacrificed and dissected for observation and classification. Based on the difference in 
gross observation, the tumors were sorted into four groups. As indicated in Figure 3-18, 
the four groups were “Small Belly” (the fish liver was larger than normal but smaller 
than those in other tumor types), “Typical” (this was a large and smooth tumor and 
majority of fish falled into this group), “Hemorrhage” (unlike the smooth tumor in the 
typical group, prominent blood vessels traversed on the surface of tumors in this type), 
“Ascites” (as mentioned before, the fish belly was extremely large and filled with fluid, 
the tumors were soft, translucent and foam-like, which was also seen in human cases).  
Totally 43 fish were sacrificed at 6 mpi and all of them had liver tumors of different 
grades. Among them, the “Typical” phenotype was the most commonly observed tumor 
at 6 mpi, accounting for 51% of the fish. About 14% mycAG transgenic fish develop the 
“Hemorrhage” phenotype. It was difficult to distinguish the “Hemorrhage” fish with 
“Typical” fish by gross observation, most of the “Hemorrhage” fish were observed in 
dissection. Notably, about 28% of the tumors shrunk in fish with “Small” phenotype. 
“Ascites” phenotype had only 7% at 6 mpi, although they were often seen at 1 mpi. 
Differences were also observed in histology examination, as shown in Figure 3-18 Q-U. 
The “Small” phenotype liver tumors showed a mixture of transformed basophilic cells 
with normal-like eosinophilic cells, while the “Typical” phenotype had uniform 
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transformed hepatocytes. Similarly, the “Hemorrhage” tumor had uniformly transformed 
tumor cells organized in a compact way, but significantly increased blood vessels were 
observed among the tissue. Finally, the “Ascites” tumors were characterized by the 
pseudoglandular organization of tumor cells.  
Based on these observation and classification, the liver tissues were collected for RNA 
extraction and qPCR. As shown in Figure 3-19, the “hemorrhage” type tumors had the 
highest mycAG transgene expression, while the expression in the small phenotype is 
much lower than the others. Unexpectedly, although the mortality was high, the mycAG 
transgene expression in the ascites phenotype was much lower than the “typical” type. 
This decrease may be due to the damage to liver function and deregulation of particular 





Figure 3-18. mycAG Transgenic Zebrafish Tumor Classification at 6 mpi. 
A. Schematic representation of experimental procedure.1 mpf fish from mycAG zebrafish were 
induced with 2 μM mifepristone. Fish were dissected to reveal the liver and then classified by the 
tumor appearance at 6 mpi. 
B to F: gross observation of fish from different treatment groups;  G to K: gross observation of 
liver under dissection microscope; L to P: GFP expression in liver; Q to U: histological 
examination. The photos were taken with the same exposure time. Driver fish with the same 




Figure 3-19. mycAG Transgene Expression in Tumors of Different Phenotypes. 
The mycAG transgene expressions in the liver samples from each phenotype were measured by 
realtime PCR and each sample had three replicates, except for the “Ascites” which had two. All 
the expressions were compared with the average myca expression in Driver liver, which is set as 
1. The error bars represent stand deriation. # indicates mycAG expression difference when 
compared with the endogenous myca expression in Driver is significant at the p-value level of 
0.05. § indicates mycAG transgene expression difference when compared with the mycAG 






3.3.2 Severe Tumor Types were observed in Long Term Expression of the 
Oncogene  
3.3.2.1 Ascites and Multinodular HCC were Similar to Human Liver Tumor 
Ascites is a syndrome with accumulation of fluid in the abdominal cavity due to some 
diseases and is often observed in human HCC cases(Cabibbo, Maida et al. 2012; Licata, 
Maida et al. 2013). The imbalance between portal blood pressure and the abdominal 
cavity pressure is one of the major causes of ascites. The blood pressure is maintained by 
albumin which is consistently produced by hepatocytes(Nazal and Cardenas 2011). 
Therefore the ascites usually indicates the lost of function of the hepatocytes (Cabibbo, 
Maida et al. 2012). 
As mentioned before, pseudoglandular type of liver tumors was observed in majority of 
mycAG transgenic fish at 1 mpi. Besides this uniform appearance in histology, many of 
these fish had an ascites syndrome (87%, 40/46), as summarized in Fig 3-20 panel A time 
line. About 6.5% fish (3/46) with ascites died around 1 mpi. Mortality of fish was only 
observed in fish with ascites. At 2 mpi, 28% fish (12/43) still had ascites among all the 
remained ones. Death was not the only reason causing decrease of the ascites phenotype. 
The ascites syndrome in majority of fish gradually and autonomously subsidized after 1 
mpi and only 7% fish had ascites at 6 mpi. 
Similar to human ascites, the serous ascites in zebrafish belly was also a clear fluid with 
pale yellow color. However, as indicated in Figure 3-19, the liver in the ascites zebrafish 
had a transparent foam-like morphology which was rarely seen in human cases. 
Histology study showed that these “bubbles” were formed by a single sheet of 
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hepatocytes, and might be filled with eosinophilic liquid sometimes. Compared to human 
liver tumors classification standards, these bubble-like tumors might be an extreme form 
of the pseudoglandular type, in which the canaliculus spaces was extremely dilated. 
Just based on gross observation, human HCC can be classified into massive type, nodular 
type and diffuse type (Rosai 2001). The massive type HCC is a single large mass, with or 
without small satellite nodules. The nodular type is composed of multiple discrete 
nodules. In comparison, the diffuse type refers the tumors with multiple minute indistinct 
nodules throughout the liver. Clinically, it is believed that tumors grossly classified as 
spreading, infiltrative or diffuse would be more rapidly progressed and would have a 
worse prognosis than those that are solitary and expanding. 
In the mycAG transgenic fish with induced myca expression for 8 to 9 months, about 
10% fish (n=31) developed the tumor similar to the diffuse type human HCC. The other 
90% showed phenotypes of “Small” (26%), “Typical” (52%), “Hemorrhage” (10%) and 
“Ascites” (3%), the same to the description in the previous section. As indicated in Figure 
3-21, the mycAG-expressing neoplastic hepatocytes were constrained by cells without 
GFP expressing. The histology results showed that these GFP-free cells were not blood 
cells or bile duct epithelial cells. Instead, it was cirrhosis formed by the increased stroma. 
In these tumors, hepatocytes developed HCC features. As shown in Figure 3-21, the 
neoplastic hepatocytes in multinodular HCC displayed much higher-than-normal 
nuclear/cytoplasm ratio, with prominent nucleoli and indistinct cytoplasmic membranes. 
The nucleus pleomorphism was much serious than ever before. Moreover, mitosis was 
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also commonly observed in these tumors. Necrosis was also observed in the center of the 
nodular, which indicated the hypoxia caused by rapid overgrowth of the tumor. 
 
Figure 3-20. Ascites in Zebrafish Liver Tumor. 
A: The time line of Ascites phenotype development in mycAG transgenic fish from 1 mpi to 6 
mpi;  
B: gross observation of the fish with ascites phenotype in monotone background;  
C: illuminated from below to show the fish belly was transparent;  
D: H&E histology of the fish presented in panel B & C;  
E & F: liver tissue from another ascites fish which exhibited transparent foam-like shape, 
photographed in GFP channel and bright field channel with below illumination respectively; 
liquid was observed in the “bubbles” of the liver;  





Figure 3-21.  Multinodular HCC with Cirrhosis and Necrosis. 
A: The time line indicates the development of multinodular HCC in mycAG transgenic fish;  
B&D: gross observation of multinodular HCC in bright field and GFP channel;  
C&E: a mass of tumor from the liver to show cirrhosis in bright field and GFP channel;  
F: confocal microscope image to show the hepatocytes with GFP and cirrhosis stroma without 
GFP;  
G-J: H&E histology of the Multinodular HCC tumor, hollow red arrows indicate the mitosis, 
while solid red arrows indicate the necrosis in these samples.  
 92 
 
3.3.2.2 WNT Signaling Pathway Activation and Epithelial Mesenchymal Transition in the 
Multinodular HCC 
The Wnt signaling pathway is a network of proteins best known for their roles in 
embryogenesis and cancer. β-catenin, a transcription factor, is the main transduction 
molecule in WNT signaling pathway and its translocation from membrane to nucleus is 
an exemplification of the activation of Wnt signaling. Clinically, β-catenin activation is 
often used for molecular diagnoses and classification of hepatocellular adenoma (HA) 
(Chu and Moon 2013). Usually, its activation indicates a high risk of malignant 
transformation in HA and is also commonly observed in HCC. The nucleus located β-
catenin was detected in the mycAG transgenic fish of 8 to 9 mpi (Figure 3-22 A and B). 
In contrast to the Driver fish liver, in which β-catenin was weakly stained, the clear and 
strong nucleus located β-catenin in the mycAG transgenic fish indicates the activation of 
WNT pathway in the mycAG transgenic fish liver tumor. 
β-catenin not only plays an important role in the WNT signaling pathway, but also be a 
key component of cytoskeleton. The β-catenin protein is the adapter that connects 
cadherin to actin cytoskeleton, and E-cadherin is one of its targets. The E-cadherin 
protein belongs to calcium-dependent adhesion protein family and mainly expressed in 
epithelial tissue. Through β-catenin, E-cadherin is connected to the membrane and plays 
an important role in cell adhesion. The decrease of E-cadherin from membrane location 
usually indicates epithelial mesenchymal transition (EMT), which is considered to be the 
first step in tumor invasion and metastasis (Jin, Chen et al. 2014). Figure 3-22 C and D 
present the E-cadherin expression changes in the zebrafish liver tumor. Compared with 
the clear membrane localized signal in Driver fish hepatocytes, the E-cadherin expression 
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in the mycAG transgenic fish was weak and rarely located on cell membrane. The loss of 
E-cadherin expression in cell membrane indicated that the transition from well-
differentiated adenoma to invasive carcinoma happened in the 8 to 9 mpi mycAG 
transgenic fish liver tumor. 
 
Figure 3-22. B-catenin and E-cadherin IHC Staining Showed the Activation of WNT 
Signaling Pathway and EMT in 9 mpi mycAG transgenic Fish Liver Tumor. 
mycAG transgenic fish liver tumor sample were collected at 8 to 9 mpi. The paraffin sections 
were stained with β-catenin (B-catenin, A & B) and E-cadherin (C & D) antibody respectively. 
The antibodies were visualized in brown to show the expression and cellular localization of the 
target protein, and nucleus were stained with blue hematoxylin. Driver fish at the same age were 
stained in parallel as control. 
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3.4 tp53M214K Homozygous Mutation Promotes Tumor Progression  
TP53 is a well-known tumor suppressor gene whose inactivation is found in more than 
50% of human tumors and its restoration could cause tumor regression in mouse model 
(Li, Zhang et al. 2014). As shown in Figure 3-17, increased apoptosis accompany 
mycAG transgene expression was observed during tumor progression. Some previous 
studies have shown that Myc could induce apoptosis through TP53 (Meyer and Penn 
2008). Therefore, whether zebrafish tp53 accounts for the mycAG transgene 
overexpression induced apoptosis in this fish liver cancer model and whether tumor 
progression is promoted when p53 is inhibited are open questions. 
Zebrafish tp53 is highly similar to mammalian TP53 in sequence, structure and function. 
As mentioned in Section 1.4.2, by using a target-selected mutagenesis strategy, a 
zebrafish line harbored a missense M214K mutation in the DNA binding domain of tp53 
was generated by Berghmans (Berghmans, Jette et al. 2005). The fish with homozygou 
tp53M214K lack cell cycle-check point response/apoptosis after γ-ray irradiation and 28% 
of these fish spontaneously developed malignant peripheral nerve sheath tumors by 8.5 
months. Thus, this zebrafish tp53M214K mutation line provides a valuable platform to 
study tp53 and its interaction with the oncogenes myca in tumor progression. 
3.4.1 Spontaneous Abnormalities were Observed in AG53 Fish  
The mycAG transgenic fish with tp53M214K homozygous mutation, named AG53 line, 
were generated according to the method described in Section 2.1.5. Similar to the 
observation in the original study(Berghmans, Murphey et al. 2005), peripheral nerve 
sheath tumor occurred spontaneously in the AG53 fish, as shown in Figure 3-23 A and B. 
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But compared to the 28% incidence rate at 8.5 mpf in the original paper, only 6% of 
AG53 fish (3/50) showed the syndrome till 16 mpf in our experiment. Besides peripheral 
nerve sheath tumors, seminoma which was not mentioned in the original literature 
(Berghmans, Murphey et al. 2005), were also observed in AG53 line spontaneously with 
an incidence of 8% in the male fish (3/38) above 12 mpf, as indicated in Figure 3-23 C 
and D. Usually this tumor only has a background incidence no more than 1% in male 
zebrafish (Spitsbergen, Tsai et al. 2000; Spitsbergen, Tsai et al. 2000). No spontaneous 
liver tumor was observed in fish with tp53M214K homozygous mutation. 
In addition to tumors, the tp53M214K homozygous mutation may also impeded embryo 
development process. Although the AG53 eggs could develop into larvae, they were 
significantly smaller than normal. As indicated in Figure 3-23 F, the left and right 
embryos present AG53 and mycAG transgenic eggs at 20 hpi respectively, and the 
former was only half size of the latter. Moreover, there was a development delay 
observed in the AG53 embryo, as the hatch-out of AG53 embryos was about 4 to 8 hours 




Figure 3-23. Spontaneous Abnormalities Observed in AG53 fish. 
Development delay and spontaneous tumors were observed in AG53 fish.  
A&B: the spontaneous peripheral nerve sheath tumor occurred in zebrafish left eye at 10 mpf;  
C&D: the seminoma in a 12 mpf male zebrafish; 
E&F: the egg abnormality and development delay in AG53 fish. Red arrows in panel E indicate 
that the embryos from mycAG line and AG53 line at 22 hpi, panel F shows the difference in size 
between embryos from these two lines. 
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3.4.2 tp53M214K Homozygous Mutation Promotes Tumor Progression in mycAG 
Transgenic Fish 
3.4.2.1 tp53M214K Mutation Might Promote Tumor Progression at Larvae Stage 
Firstly, the mycAG transgene expression in these mycAG and AG53 transgenic fish was 
compared. The larvae from these two lines were induced from 3 dpf with 2 μM 
mifepristone, and then sacrificed at 5 dpi for RNA extraction and qPCR. As shown in 
Figure 3-24, the mycAG transgene expression in mycAG line and AG53 line were 
comparable. Moreover, in both mycAG transgenic fish and AG53 fish, mycAG 
expression was much significantly higher than the endogenous myca. 
The liver morphology of the larvae was also examined at 5 dpi. The larvae of Driver fish 
and Driver fish with tp53M214K homozygous mutation (named as “Driver53”) were used as 
control. As revealed in Figure 3-25, the livers of the Driver53 larvae were significantly 
smaller than the Driver, and this might be due to the development delay in these fish with 
p53M214K homozygous mutation. The livers of the mycAG and AG53 line larvae were 
significantly larger than those of Driver control, but there was no observable difference 
between these two lines. However, if the developmental delay in AG53 fish was taken 
into consideration, the liver overgrowth in AG53 fish actually was more prominent than 
that in mycAG fish.  
The survival rates of these larvae were recorded till 10 dpi and the survival curve was 
plotted in Figure 3-26. It shows that compare to the control, the mortality in either 
mycAG transgenic line or AG53 line was significantly increased. Although the 
developmental process delayed in fish with p53M214K homozygous mutation, the survival 
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of Driver53 fish was not affected. Larvae from this line had a similar survival rate 
compared to the larvae of the Driver line. 
 
Figure 3-24. mycAG Transgene Expression in the mycAG and AG53 Fish. 
mycAG line and AG53 line larvae were treated with 2 μM mifepristone from 3 dpf. Larvae were 
collected at 5 dpi for RNA extraction, and each group has three biological replicates. Transgenic 
mycAG transgene expression was measured by qPCR. All the expressions were compared with 
the average myca expression in Driver, which is set as 1. The error bars represent stand deriation. 
# indicates the expression differences when compared to endogenous myca expression in Driver 





Figure 3-25. AG53 and mycAG Transgenic Larvae Liver Size Comparison. 
A: zebrafish larvae from mycAG, AG53, Driver and Driver 53 transgenic lines were treated with 
2 μM mifepristone from 3 dpf. The livers were illustrated with GFP signal and double transgenic 
fish also express strong mCherry in eyes which could be seen under GFP channel. All the fish 
were photographed at the same magnification and with the same exposure time. 
B: their liver size was measured according to the method in Section 2.1.7 at 5 dpi/8 dpf. The error 
bars represent stand deriation. ## and # indicate the liver size difference when compared with the 
Driver53 is significant at the p-value level of 0.01 and 0.05 respectively. §§ and § indicate the 
liver size difference when compared with the Driver is significant at the p-value level of 0.01 and 
0.05 respectively. ++ indicates the liver size difference when compared with the AG53 is 




Figure 3-26. AG53 and mycAG Transgenic Larvae Survival Curve Comparison. 
Zebrafish larvae from mycAG, AG53, Driver and Driver53 transgenic line were treated with 2 
μM mifepristone from 3 dpf and their liver size were followed daily till 10 dpi. Lines of different 
color in the figure represent the survival curve of each transgenic fish. ## indicates the survival 
difference when compared with the Driver is significant at the p-value level of 0.01; §§ indicates 












3.4.2.2 tp53M214K Mutation Promotes Tumor Progression in Adult Zebrafish 
The subtle developmental delay caused by p53M214K mutation became insignificant by 1 
mpf and the effect of tp53 mutation on liver tumor progression was much easier to 
observe from 1 mpf. To exam the tumor progression in adult liver, a new batch of fish 
was induced from 1 mpf with 2 μM mifepristone. As shown in Figure 3-27, the 
difference between AG53 and mycAG transgenic fish became evident as early as 0.5 mpi. 
Moreover, the tumor phenotype of the AG53 fish was also different with the mycAG line.  
As shown in Figure 2-27, it is apparent that the body size of the fish from both mycAG 
and AG53 transgenic line were significantly smaller than the Driver fish. The evident 
enlargement of belly of the AG53 fish could be grossly observed as early as 0.5 mpi, 
while the mycAG transgenic fish had not shown any apparent changes from gross 
observation at this stage. The fish were then sacrificed and dissected to exposure the liver. 
The liver of the AG53 had grown into an apparent mass all over the belly at 0.5 mpi. In 
contrast, the liver of mycAG transgenic fish was just enlarged a little bit compared to the 
Driver line fish. When the fish were induced for 1.5 month, different tumor phenotypes 
were developed in these two lines. As exampled in Figure 3-27, the fish of mycAG 
transgenic line developed tumors with ascites. In contrast, the tumor progression in AG53 
fish was very fast resulting in a firm and compact tumor type.  
These differences were reflected in histology too. As shown in Figure 3-28, the 
neoplastic hepatocytes in both AG53 and mycAG transgenic fish were similar in the 
characteristics of basophilic cytoplasm, enlarged nucleus and prominent eosinophilic 
nucleoli. Cell density increased in both lines too. The cell plate structure in AG53 fish 
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was more seriously distorted and so the tumor in AG53 was diagnosed as HA while in 
mycAG transgenic fish it was just hyperplasia. Furthermore, at 1.5 mpi, the liver tumor 
cells in AG53 fish were jumbled together and organized into compact type, while 
majority of the mycAG expressing liver tumor was a typical pseudoglandular type with 
ascites which was similar to the previous observation as shown in Figure 3-28. This 
compact organization of hepatocytes in AG53 fish at 1.5 mpi significantly changed the 
normal liver tissue organization and was also considered to be the evidence for early 
HCC formation.  
 
Figure 3-27. Gross Observation Comparison of Tumor in mycAG fish and AG53 Fish. 
1 mpf fish from mycAG line and AG53 line were induced with 2 μM mifepristone photographed 
at 0.5 mpi and 1.5 mpi. A to E: the gross observation of fish  from different transgenic lines at 
different time points. F to J: gross observation of the liver which was recorded by the dissecting 





Figure 3-28. The Histology of mycAG Transgenic Fish and AG53 Fish Liver Tumors. 
1 mpf fish from mycAG line and AG53 line were induced with 2 μM mifepristone from 1mpf and 
sacrificed at 0.5 mpi and 1.5 mpi. The entire fish were collected for histology study. The slides 












3.4.2.3 Less Apoptosis was Observed in AG53 Fish 
Many studies have demonstrated that TP53 pathway plays an important role in Myc-
caused apoptosis(Hoffman and Liebermann 2008). It is thus hypothesized that the 
apoptosis in mycAG transgenic fish could be inhibited by introducing the p53M214K 
mutation. To exam the apoptosis, liver samples from 2 mpi/3 mpf mycAG transgenic line 
and AG53 line were collected for TUNEL assay. The intestine tissue in the same section 
was used as positive control, as intestine epithelial cells undergo a consistent apoptosis 
under a normal physiological condition. As shown in Figure 3-29, compared to the Driver 
liver which rarely had apoptosis signals, apoptosis was observed in both AG and AG53 
lines. But the apoptosis signals in AG53 fish was significantly less than that in the 
mycAG transgenic fish. This result showed that the tp53M214K homozygous mutation 
could block part of the myc caused apoptosis, and at the same time, some apoptosis 






















Figure 3-29. Apoptosis was Observed in AG53 and mycAG Transgenic Fish Liver. 
1 mpf mycAG fish were induced with 2 μM mifepristone, and then were sacrificed at 2 mpi for 
TUNEL staining. Intestine tissue in the samples was used as positive control, Driver fish liver 
was used as normal condition control. All the slides were observed and recorded under light 
microscope. Each group has 3 to 4 biological replicates and apoptosis were counted and 
represented in column. The error bars represent stand deriation. ＃＃, indicates the difference in 
proliferation when compared with Driver is significant at the p-value level of 0.01. §§,  indicates 




3.5 Liver Tumor Could Regress in Both mycAG fish and AG53 Fish  
In many tumor models, people noticed that inactivation of the deregulated oncogene may 
be sufficient to reverse the tumorigenesis process. This phenomenon named as “oncogene 
addiction” confirms the critical role of a specific oncogene in the maintenance of 
complicated tumor growth and survival process (Weinstein 2002) and provides a 
promising therapeutic approach by molecular targeting. Addiction to Myc expression also 
has been revealed in many studies (Jain, Arvanitis et al. 2002; Wu, van Riggelen et al. 
2007). However, the addiction to Myc in liver tumor has been rare studied. Here, the 
mycAG and AG53 transgenic zebrafish liver tumor models established by LexPR 
inducible system enable the inactivation of mycAG transgene expression by withdrawing 
mifepristone. Furthermore, in AG53 transgenic fish, the tp53M214K homozygous mutation 
was introduced to mimic a more realistic situation of tumor initiation and progression. 
Thus the mycAG and AG53 transgenic fish provide us a nice platform to investigate Myc 
addiction effect in fish HCC as well as in a tp53 mutant background. 
3.5.1 Rapid suppression of mycAG Transgene  Expression After Mifepristone 
Withdrawal 
To examine whether the zebrafish liver tumors were addicted to mycAG transgene 
expression, the inducer mifepristone was withdrawed at 6 mpi from mycAG transgenic 
line and AG53 line. At 6 mpi, all the AG53 fish had uniformly super-enlarged belly. In 
contrast, the mycAG transgenic line fish phenotypes were more diverse. As described in 
Section 3.3.1.2, the tumor in some mycAG transgenic fish became smaller spontaneously 
in mycAG transgenic line. To make the comparison more comparable, only the mycAG 
transgenic fish with significant enlarged belly were selected for regression, which 
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included “Typical”, “Hemorrhage” , and “Ascites” type, as classified in Section 3.3.1.2. 
As the LexPR system was highly sensitive to mifepristone, the fish were washed third 
times and kept in flow-through water to eliminate all the residual mifepristone. Fish were 
sacrificed at 0 days post removal of mifepristone (record as “0 days post regression (0 
dpr)”), 8 dpf and 18 dpr for sampling. Driver fish without induction were used as control.  
As shown in Figure 3-30, the GFP signal faded away fast after the mifepristone withdraw. 
Only very faint GFP could be observed at 8 dpr in the mycAG and AG53 transgenic fish 
liver and almost no GFP could be detected at 18 dpr. Moreover, the liver size decreased 
gradually in both transgenic lines after the mifepristone withdrawal, while the body size 
and length increased significantly. No fish death was observed during tumor regression. 
The livers were collected at each time point for RNA extraction and mycAG transgene 
expression changes in hepatocytes were measured by qPCR. As shown in Figure 3-31, 
with the removal of mifepristone, the mycAG transgene expression decreased 
dramatically at mRNA level. At 18 dpr, the mycAG transgene expression was 




Figure 3-30. Gross Observation of Tumor Regression in mycAG Transgenic fish and AG53 fish. 
The mifepristone was withdrawed at 6 mpi, fish from mycAG line and AG53 line were sacrificed at 0 dpr, 8 dpr and 18 dpr for sampling. Row A, 
gross observation of fish during regression. Then fish were dissected to reveal the liver, and were recorded by the camera of dissecting microscope 




Figure 3-31. mycAG Transgene Expression in the mycAG and AG53 Transgenic Fish Liver 
after Mifepristone Withdrawl. 
The mifepristone was withdrawal at 6 mpi, fish from mycAG line and AG53 line were sacrificed 
at 0 dpr, 8 dpr and 18 dpr for RNA extraction. Each group had three biological replicates. 
Transgenic mycAG expression was measured by qPCR. All the expressions were compared with 
the average myca expression in Driver, which is set as 1. The error bars represent stand deriation. 
## and # indicate the expression difference when compared with myca expression in Driver is 










3.5.2 Tumor Regressed in Both mycAG and AG53 Transgenic Fish 
3.5.2.1 Morphology of Hepatocyte Became Normal after Mifepristone Withdrawl 
The gross observation revealed a typical oncogene addiction effect in these zebrafish 
mycAG transgenic liver tumor models. The tumor could regress when the ectopic 
oncogene expression was suppressed. Interestingly, the regression also occurred in the 
tp53 M214K homozygous mutation background.  
To further characterize the tumor regression and hepatocyte changes, the fish were 
sacrificed for histological examination. As shown in Figure 3-32, at 6 mpi, majority of 
AG53 fish developed a typical compact liver tumor. The hepatocytes composed the 
AG53 fish liver tumors were characterized with basophilic cytoplasm, distinct 
eosinophilic nucleus and prominent nucleoli, which was similar to the observation of 
mycAG transgenic fish tumor. These neoplastic cell phenotypes were reverted to normal 
when mycAG transgene expression was suppressed. At just 8 dpr, these neoplastic 
hepatocytes had a normal appearance with an eosinophilic pink cytoplasm and a 
basophilic nucleus, and the size of the nucleus shrunk too. Although at 18 dpr the 
organization of the hepatocytes in mycAG transgenic line and AG53 line were still show 
an abnormal sheet-like pattern, the appearance of the cells was the same as the control. 
Hepatocytes normally contain some granules with glycogen or other proteins produced 
by hepatocytes, and the number and size of the granules may vary and depend on diet and 
gender. These granules were also observed in the mycAG transgenic line and AG53 line 





Figure 3-32. Histology of Liver Tumors Regression in mycAG fish and AG53 Fish. 
The mifepristone was withdrawed at 6 mpi, fish from mycAG line and AG53 line were sacrificed 
at 0 dpr, 8 dpr and 18 dpr for sampling. Driver fish without induction were used as control. The 









3.5.2.2 Apoptosis was Observed in Both mycAG and mycAG53 Fish 
Many studies have shown that oncogene addiction and tumor regression were dependent 
on the tp53 signaling pathway. However, even the tp53 gene was homozygously mutated 
in the AG53 line, regression still occurred when mycAG transgene expression was 
stopped. To examine whether apoptosis was involved in the regression, TUNEL assay 
was applied to the regression fish. As can be seen in Figure 3-33, apoptosis was rare in 
control livers, but it accompanied the tumor progression in mycAG transgenic fish and 
the apoptosis was significantly increased in the regression process. Compared to the 
mycAG line fish, almost the same level of apoptosis was also observed in AG53 fish liver 
tumor regression. Therefore, these observations indicated that some pathways other than 






Figure 3-33. Apoptosis in AG53 and mycAG Transgenic Fish Liver in Regression. 
A to F: The mifepristone was removed at 6 mpi, fish from mycAG line and AG53 line were 
sacrificed at 0 dpr, 8 dpr for paraffin section and TUNEL staining. Driver fish without induction 
were used as control.  Intestine tissue in the samples was used as positive control. G: Each group 
has 2 to 3 biological replicates and apoptosis were counted and represented in column. The error 
bars represent stand deriation. ＃ and ＃＃, indicate difference when compared to Driver 0 dpr is 
significant at the p-value of 0.05 and 0.01 respectively. § and §§, indicate difference when 
compared to Driver 8 dpr is significant at the p-value of 0.05 and 0.01 respectively. ※ indicate 
difference when compared with AG 0 dpr is significant at the p-value of 0.05.  
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Chapter 4   Discussion 
4.1 The Application of Mifepristone Inducible LexPR System in 
Zebrafish 
4.1.1 Toxicity of Mifepristone 
Mifepristone (RU-486), the first synthetic steroid, has been successfully used for clinical 
termination of pregnancy for more than a quarter of a century and its function is 
antagonizing progesterone by competing for its receptors(Spitz 2010). In the transgenic 
zebrafish in this study, besides the engineered chimeric LexPR transcription factor, it also 
has endogenous progesterone receptors which could bind with mifepristone. As the 
sufficient concentration for expression activation is at least 1 nM (429.6 
ng/L)(Emelyanov and Parinov 2008) which is much higher than many environmental 
studies of no more than 100 ng/L(Bluthgen, Castiglioni et al. 2013; Bluthgen, Sumpter et 
al. 2013), it is necessary to be tested before the experiment.  
Our current studies about the impact of mifepristone with a wide range of concentration 
from 2 µM to 70 µM in zebrafish larvae and adult fill in this research gap. It showed that 
up to 6 µM (25.8 µg/L) could be safe to zebrafish larvae. However, edema was observed 
in the larvae. One possible explanation of the dramatically increase of edema could be the 
role of mifepristone as glucocorticoid receptor antagonist. It is found that mifepristone 
can affect ion intake in rainbow trout gill epithelia in a dose dependent manner up to 14 
µM(Kelly and Chasiotis 2011). So the high concentration of mifepristone might also 
account for the imbalanced osmotic pressure in zebrafish larvae and edema.  
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Besides development delay in high mifepristone concentration at larvae stage, the impact 
of mifepristone on zebrafish, especially the liver, is not obvious in histology and mRNA 
expression. Some studies have revealed that mifepristone may targeted at the 
reproductive tissue (testes and ovaries) and just environmental level mifepristone at 77 
ng/L (0.18 nM) might affect the reproduce activity of zebrafish (Bluthgen, Castiglioni et 
al. 2013; Bluthgen, Sumpter et al. 2013). Decrease of egg and sperm production was 
observed in histological examination in this study. But as the mifepristone treated fish 
were not used for breeding in the present study, the impact of mifepristone on gonad was 
not focused and studied here.  
In summary, our data demonstrated that up to 5 µM mifepristone has no observable side 
effects on both larvae and adult zebrafish liver morphology and endogenous myc gene 
expression. Therefore, the mifepristone inducible LexPR system is safe for the transgenic 
liver tumor study in zebrafish.  
4.1.2 Expression Efficiency of LexPR System 
The observable GFP in Driver fish at different mifepristone concentrations enable a brief 
study of expression kinetics of the LexPR system. Firstly, we found that the transgenic 
LexPR system could be activated in both larvae and adult stage and the LexPR system is 
very sensitive to mifepristone induction and responds quickly. But the expression of GFP 
in Driver fish liver saturated at very low concentration and limited its potential 
application in transgene expression level adjusting. The LexPR system also enables a 
tight control of transgene expression. After mifepristone withdraw, the GFP fade away 
very fast and became invisible in hepatocytes within 10 days. The mRNA level decreased 
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at a relatively slow rate, the amount of which was still significantly higher than 
endogenous myca at 8 dpr (p=0.05). This observation suggests a high affinity of 
mifepristone to LexPR transactivator or a high stability of LexPR transactivator, both of 
which might keep the transcription of transgenic oncogene. But the transcription of the 
LexPR system would finally drop to the basal level within 18 dpr. All in all, although the 
switch-off is much slower than its induction, the LexPR system could be applied to study 
the effect of oncogene expression and also the tumor status after the oncogene expression 
decrease.  
4.2 Zebrafish myca and mycb Oncogenicity Comparison 
4.2.1 myca and mycb are Highly Divergent 
According to the 3R hypothesis, after the divergence of fish with the other vertebrates, a 
whole genome duplication occurred in teleost around 350 Ma ago (Ma: Mega-annus, the 
unit of time equal to 106 years)(Christoffels, Koh et al. 2004; Jaillon, Aury et al. 2004), 
which resulted in additional copies of genes. Compared to mammalians’ single Myc gene, 
the phylogenic analysis of fish myc gene family indicated that two paralogous myc gene, 
myca and mycb, arose from a common ancestor in this fish specific genome duplication 
(Marandel, Labbe et al. 2012). Due to the selective pressure, the fate of the duplicated 
paralogs might be different. In a phylogenic analysis using amphioxus (Branchiostoma 
floridae) Myc protein sequence as the outgroup, it has been found that Myca is much 
stable in both sequence and synteny across teleost species. In contrast, Mycb undergoes a 
rapid evolution and become more diverse in species such as medaka, tilapia and seabass, 
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and even lost entirely or partially in the genomes of fugu, tetraodon and stickleback 
(Marandel, Labbe et al. 2012).  
The zebrafish myca and mycb locate at the chromosome 24 and 2 respectively. As an 
transcription factor in response to growth signals, myca and mycb are usually expressed 
in developmental process and mostly in mitosis hotspots such as retina, cerebellum, 
forebrain, branchial arches and pectoral fin buds(Meijer, van der Sar et al. 2008). 
However, both others’ and our data also revealed the difference between myca and mycb 
expression. For example, in early stage development, myca expression is mainly found in 
brain while mycb is found in lateral line neuromasts(Meijer, van der Sar et al. 2008) . In 
the zebrafish ciliary marginal zone, the expressions of most myc family members have 
been detected and myca is especially required to maintain the continuous replacement of 
new cells. In contrast, no mycb expression in this process has been detected (Xue and 
Harris 2012). In our study as shown in Figure 3-6, great divergence of expression was 
also found between myca and mycb in adult zebrafish liver and the expression of mycb is 
about 10 times higher than myca. These distinct expression patterns suggested the 
physiological function of the two zebrafish myc paralogous might be very different. 
As protein function is tightly related with its sequence and structure, protein sequence 
analysis could predict possible biological function of poorly studied proteins. The 
sequence alignment and phylogenic analysis of zebrafish Myca and Mycb shown in 
Figure 3-7 and 3-8 indicate that most structure motifs and functional domains of these 
two paralogs are highly conserved, except for the LZ domain. The evolutionary distance 
of this LZ domain between these two zebrafish paralogous is much larger than that 
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between human and mouse. Based on this finding, it is reasonable to suspect that after 
WGD, each domain of zebrafish Myca and Mycb might had different evolutionary 
pressures and the LZ motif underwent a rapid evolution under a higher pressure.  
The LZ motif commonly exists in many transcription factors and is characterized with 
multiple leucine (Leu, L) residues at approximate 7-amino-acid intervals which are 
named from a to g. These regularly repeated leucine resides, which locate at the d 
position of these heptad repeats, provide a hydrophobic region for dimerization with 
other LZ motif containing proteins(Amoutzias, Robertson et al. 2008) and all of them are 
also conserved between zebrafish Myca and Mycb, as shown in Figure 4-1. Besides the d 
position Leu, residues at position a are also important for the function of Myc protein, the 
first three of which are usually amino acid with charged R group and prevent the 
formation of homodimers(Beaulieu, McDuff et al. 2012). In zebrafish Myca and Mycb, 
most a position residues are identical except for the 406 Serine (S) of Myca and the 384 
cysteine (C) of Mycb, as shown in Figure 4-1. This difference is noticeable because the 
Serine and cysteine amino acids have disparate biochemical traits: the hydroxyl group of 
serine frequently provides phosphorylation site while the thiol of cysteine often forms 
disulfide bond, and both of which has great impact on protein function(Lehninger 2004). 
Moreover, the human MYC protein has a positive charged arginine at the same position. 
Although both residues in the zebrafish paralogous are still uncharged amino acids, 
according to the hydropathy index (Kyte and Doolittle 1982), the serine (index = -0.8) is 
still much more hydrophilic than cysteine (index = 2.5)(Lehninger 2004). So it might 





Figure 4-1 Myca and Mycb protein LZ motif comparison 
The LZ motif of myca and mycb were compared. Identical amino acids were labeled in blue. The 
scale above and below the sequence indicates the position of the amino acid in the whole protein; 
above is for myca and the below is for mycb. The conserved leucine amino acids were labeled in 
red square, which are also the d position residues and the a position residues were labeled in 
green square. 
The transgenic expression of GFP fused Myca and Mycb in our zebrafish model also 
revealed their difference in cellular localization. The recombinant GFP (Gene Bank 
Access #. U57607) is a 32.7 kDa monomer protein. In cells, GFP is freely and evenly 
diffused in the cytoplasm and nucleus (Zhang, Gurtu et al. 1996; Park and Lee 2013). 
Similar distribution pattern of empty GFP was also observed in the zebrafish Driver fish 
hepatocytes, as shown in Figure 3-11D&F. In contrast, nucleus GFP signal was observed 
in the hepatocytes of the mycAG transgenic line fish, as shown in Figure 3-11G&I, which 
is believed to be the GFP fused Myca protein. Freely distributed GFP similar to Driver 
hepatocytes was also observed in the hepatocyte cytoplasm in the mycAG transgenic fish. 
This could be the non-fusion GFP, as both non-fusion GFP and GFP-Myca fusion protein 
were expressed together in the mycAG transgenic fish liver. Similarly, both cytoplasm 
and nucleus localized GFP signals were observed in the mycBG fish hepatocytes, as 
shown in Figure 3-11J&L. However, this nucleus localized GFP signal was only 
observed in a few of the mycBG hepatocytes while in most of the mycBG hepatocytes, 
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the GFP signal was freely distributed like in the Driver fish. Based on these observations, 
it could be inferred that the Myca protein is definitely a nucleus localized protein while 
Mycb protein is less efficient in nucleus localization. The differences between mycAG 
and mycBG protein nucleus localization might also be due to improper expression and 
folding of the transgenic protein. Therefore whether Mycb has function in cytoplasm and 
how it is transported to nucleus required more investigation.  
4.2.2 Both mycAG and mycBG are Oncogenic in the transgenic lines 
Although zebrafish Myca and Mycb have many differences in sequences, endogenous 
expression and cellular localization, our data showed that both of them are still oncogenic 
in zebrafish hepatocytes, and their transgenic expression resulted in increased larvae 
lethality and tumor growth, as shown in Figure 3-12 to Figure 3-15.  
However, the tumor observed in transgenic mycAG fish grew much faster and also 
reached a more advanced stage than in mycBG fish. On one hand, the differences may be 
due to their divergent natural function, as analyzed earlier; on the other hand, it might 
attribute to the expression level of mycAG and mycBG transgene. Higher expression of 
mycAG transgene than mycBG was revealed by gross observation and qPCR, as shown 
in Figure 3-12 to 3-15. Usually, the number of insertion sites, total copy number and 
genomic context around the insertion site are the major factors that affecting transgene 
expression. The genotyping results in Table 3-1 and 3-2 showed that mycAG transgenic 
fish have at least two insertion sites in genome while mycBG fish have only one. Thus, 
the insertion numbers might be responsible for the differences in transgene expression in 
these two lines, as well as subsequent performance in tumor growth. 
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Moreover, the hepatocytes may be easily disturbed by increased expression of transgenic 
Mycb. With 2 μM mifepristone induction, the expression of mycAG transgene was about 
100 times higher than endogenous myca in normal condition (Driver) while mycBG 
expression was only twice of the endogenous mycb in Driver and fourth of its own 
endogenous mycb, as shown in Figure 3-10. Overgrowth of liver was observed even in 
the mycBG fish induced with as low as 0.005 μM mifepristone, as shown in Figure 3-14, 
which only exhibited very faint GFP signal. Many other studies have indicated that the 
expression of an oncogene should surpass a critical threshold to cause malignant 
transformation (Elenbaas, Spirio et al. 2001). Therefore, in the case of these mycBG 
transgenic fish, the oncogenic threshold for Mycb is very low compared to its normal 
expression. Thus it also could suspect that the Mycb expression in normal hepatocytes 
should be tightly controlled. 
4.3 Comparison of Transgenic Zebrafish Liver Tumors with Human 
HCC 
Histology-based liver tumor classification is the most important technique in human HCC 
diagnosis. A mature standard has been established for human HCC grading (Kamal G. 
Ishak 2001), and even have been successfully applied in diagnosis of rodent liver tumor 
models (Resources 1980; Goodman, Maronpot et al. 1994). In recent years, many 
zebrafish liver malignant transgenic lines have been generated. However, one of the 
major limitations in application of these zebrafish cancer models might be the lack of 
universal classification criteria similar to those used for human and the rodents. Therefore, 
it would be necessary to make a thorough comparison of the histological properties 
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between zebrafish and human liver tumors, which might be useful for malignant lesions 
classification in the future. 
Grossly, in contrast to the distinct lobular organization of liver tissues in mammals, 
zebrafish liver is organized in a tubular pattern with uncommon portal triads. Hepatocytes 
are the main part of liver, as well as the major studied targets in this project. Like the 
hepatocytes in human, rat and mouse, the normal hepatocytes of zebrafish are polyhedral 
cells arranged in plates of two cells thick and separated by sinusoids and usually have one 
basophilic nucleus and eosinophilic cytoplasm containing glycogen, hemosiderin or 
lipofuscin granules, as shown in Figure 3-15. As one important function of hepatocytes in 
both mammal and fish is bile secretion, tiny bile canaliculi exist between hepatocytes to 
collect the bile, which then converge into the micro bile duct which scattered in the liver. 
Therefore, the biliary epithelial cells lining bile ducts are the second most common cell 
type and can be observed under a light microscope. As shown in Figure 3-16, biliary 
epithelial cells are cuboidal cells with round nucleus, and could be easily distinguished 
from hepatocytes for its smaller size and more basophilic staining. Blood cells and blood 
vessel epithelial cells are also often observed in liver tissues, as well as the endothelial 
cells that line the hepatocytes to form the sinusoids. A few other cell types also exist, 
such as microphages and lymphocytes, but they are normally inconspicuous in H&E 
staining.  
In human and carcinogen treated rodents, the liver tumors are usually formed with foci of 
hepatocyte alteration. The affected area is from 10-12 cells to large foci which can be 
seen as a 1-2 mm pale spots on the liver surface (Resources 1980; Goodman, Maronpot et 
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al. 1994; Kamal G. Ishak 2001). According to the H&E staining appearance, the foci are 
classified as basophilic, eosinophilic, clear cells or mixed type. The hepatocytes in foci 
can be either larger or smaller than the normal ones, but the alteration of their 
organization are usually imperceptible. Moreover, there is no distinct boundary between 
the foci and normal liver tissues. The foci do not press the surrounding area and this is an 
important trait distinguished from the hepatocellular adenoma. However, foci lesions 
were not observed in this transgenic zebrafish liver tumor models. This might because 
that the transgenic oncogene is universally expressed in all the hepatocytes, and therefore, 
unlike nature occurred tumor originated from several transformed cells, all the 
hepatocytes would be transformed together at the very beginning of oncogene expression.  
The hepatocyte hyperplasia is a manifestation of the second stage of 
hepatocarcinogenesis in many animal models (Kamal G. Ishak 2001), although this lesion 
is still a benign change. This kind of lesion varies in size, and usually is a round pale or 
tan nodule elevated above liver surface and has a clear boundary with adjacent normal 
tissue in human and mouse/rats cases. The hepatocytes in hyperplasia lesion could be 
either basophilic or eosinophilic, or a mixture of both. Usually the nucleus is enlarged 
with a prominent nucleolus in center. Mitosis is observed occasionally in hyperplasia. 
The two-cell-thick organization of hepatocytes is changed in a way that the sinusoid 
space become either dilated or compressed than normal. In microscopic observations of 
human and rodent samples, the hyperplasia lesion rarely compresses surrounding tissue. 
Typical hyperplasia has been observed in the mycBG transgenic fish, as shown in Figure 
3-15, which manifested as basophilic cytoplasm and prominent nucleoli and mitosis. 
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Hepatocellular adenoma (HA) is a benign neoplastic lesion. It can be a big solitary lesion 
which replaces a significant amount of liver or occupies several nodules in human. The 
cytoplasm of HA hepatocytes is usually either more eosinophilic or basophilic than 
normal, and sometimes contain foamy vacuoles. Loss of normal hepatic one cell thick 
plates is observed in HA, and the hepatocytes are organized in cord or sheets instead. The 
nucleus may be enlarged, but are typically in uniform morphology in the whole tumor. 
Mitosis is rarely observed in HA. The HA has a sharp boundary and always compress the 
surrounding tissue. Typical HA developed in early stage of mycAG transgenic fish. Due 
to the universal even expression of transgenic oncogene, the whole liver was transformed 
into HA. Therefore, instead of compressing surrounding normal tissue, compression of 
the blood vessel could be observed in transgenic liver tumor models, as shown in Figure 
3-15E. 
Hepatocellular carcinoma (HCC) is a malignant liver neoplasm, which rarely happened 
spontaneously in nature situation in zebrafish liver, but has been observed in fish with 
carcinogen treatment. It tends to be a spherical lesion but usually has a rough surface and 
irregular border. Microscopically, the cells of early stage HCC may resemble the normal 
hepatocytes, and the well differentiated tumor cells are difficult to be distinguished from 
the normal ones. Mitosis is frequently observed in HCC. Cellular atypical and 
polymorphology of nucleus also increases with tumor progression. Moreover, tumor 
invasion, for example, into the blood vessels, is an important sign to demonstrate this 
malignant lesion. The tumor cells in HCC are organized in some specific patterns. The 
Trabecular pattern is the most common one. The liver tumor resembles the normal 
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tissue structure and form cell plates, but the rapid proliferation makes the plates thicker 
than normal and compress into trabeculae. When the over proliferation further compress 
the “sinusoid” between the trabeculae, it will cause the trabeculae growing into a sheet of 
tumor cells, and this solid tumor is classified as compact pattern.  In some 
circumstances, the canaliculus in the center of the trabeculae may be inflated rather than 
compressed, and form the pseudoglandular pattern in which the neoplastic hepatocytes 
mimic gland cells and surround a center clear space.  Bile or eosinophilic material is 
frequently observed in the dilated canaliculi. Both compact and pseudoglandular 
organization has been observed in this mycAG transgenic fish, as shown in Figures 3-16, 
3-18, 3-20, and the details of these tumors will be discussed in the next section.  
4.4 mycAG Overexpression Caused Zebrafish Liver Tumor 
As the tumor progression is much faster and the tumor is more severe than the mycBG 
fish, in this project the mycAG transgenic fish were selected for further studies. These 
zebrafish liver tumors caused by mycAG transgene expression manifested many specific 
traits as well as some characteristics similar to human liver cancers. 
4.4.1 mycAG Transgene Overexpression Induced Apoptosis was Observed in the 
Liver Tumor Progression 
Firstly, accompanied with the over expression of mycAG transgene and the increase of 
cell proliferation, increased apoptosis was also observed in the zebrafish liver tumor, as 
shown in Figure 3-17. Increase of apoptosis and senescence are also frequently observed 
in many other animal models or cell lines with oncogene deregulation. This phenomenon 
may be due to the elevated proliferation which increases genome instability, aggravates 
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cellular stress and thereafter activate apoptosis apparatus (Hills and Diffley 2014). In 
normal conditions, this innate apoptosis property of oncogene plays an important role as 
safeguard to prevent deterioration of oncogene deregulation and helps to clean the 
unwanted damaged cells.  
The Myc provoked apoptosis has been observed in many tumors (Hoffman and 
Liebermann 2008). As resistance to apoptosis is important for tumor initiation, many 
studies suspected the oncogenicity of Myc to initiate the cascade of tumors progression 
independently. Severe apoptosis also has been observed in this transgenic zebrafish liver 
tumor model, as shown in Figure 3-17. However, HCC still developed in this model at 
the end. This demonstrated that the oncogenicity of zebrafish myca is able to overwhelms 
its innate mistake checking machinery and initiate malignant status. One possible 
mechanism is that the over expression of myca increases apoptosis and forms selective 
pressure, while on the other hand it also increases genome instability and provides plenty 
of gene mutations for selection. Finally tumor cells with apoptosis-inhibition mutations 
will survive and progress into more serious stage.  
In addition, people found that introducing a secondary mutation to attenuate MYC 
induced apoptosis might be necessary for successful malignant transformation (Beverly 
and Varmus 2009; Loosveld, Bonnet et al. 2014). Similarly, in this project we observed 
that introducing a tp53M214K homozygous mutation which could almost completely 
abolish apoptosis would significantly accelerate the tumor progression, as shown in 
Figure 3-25, 26, 27. TP53 has been found to play an axial role in Myc caused apoptosis 
(Larsson and Henriksson 2010). In response to DNA damage, both TP53 expression and 
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protein stability is increased (Takaoka, Hayakawa et al. 2003). The accumulated TP53 
protein cause cell cycle arrest and stimulate apoptosis related gene expression (Amaral, 
Xavier et al. 2010). In mammals, Myc expression has direct impact on TP53 stablization 
by up-regulate ARF (ADP-ribosylation factor), which is an antagonism of TP53 
degradation protein Mdm2(Amaral, Xavier et al. 2010). Similarly, apoptosis decrease and 
tumor progression acceleration in our AG53 fish also indicated a relationship between 
zebrafish myca and tp53. However, a recent study reported that functional arf ortholog 
does not exist in zebrafish genome (Gutierrez, Look et al. 2014) as they observed that 
tp53 homozygous mutation has no impact on Myc induced T-cell acute lymphoblastic 
leukemia (T-ALL) and the phenotype was similar to the observation in Arf-deficient mice. 
Other explaination to their studies could be the dissimilarity of tumor types and animal 
models. However, a potential connection between myca and tp53 which might be 
independent of arf may exist in zebrafish. 
4.4.2 Divergent Phenotypes of Liver Tumor were related with mycAG Expression 
Divergent tumor phenotypes have been observed in this mycAG transgenic fish and 
which might be associated with the transgenic mycAG expression level. At least four 
types of liver tumors, “Small”, “Typical”, “Hemorrhage” and “Ascites”, were observed in 
the mycAG transgenic fish at 6 mpi. Notably, the divergent tumor phenotypes were 
developed during tumor progression. At the tumor initiation stage within one month, all 
the fish displayed similar phenotypes with significant enlargement of liver and 
transformation of hepatocytes, and majority fish displayed the “Ascites” phenotype at this 
stage, as shown in Figure 3-16, 3-18, 3-20, 3-21and the description in section 3.3.1 and 
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3.3.2, However, the percentage of “Ascites” was decreased thereafter. Besides some fish 
death, it seemed that most “Ascites” tumors were transformed into the other three types 
gradually. 
The divergent tumor types and severity might be associated with levels of mycAG 
transgene expression in individual fish. The “Small” phenotype which showed mixed 
normal and transformed hepatocytes at the histological level has the lowest mycAG 
transgene expression, while the highest mycAG transgene expression was found in firm 
tumor “Hemorrhage” type with criss-cross blood vessels on the surface, as shown in 
Figure 3-18 & 3-19. Actually, the relationship between oncogene 
amplification/expression level and tumor grade has been demonstrated in many clinical 
and animal model studies. For example, the expression level of EGFR protein is coherent 
with the grading of human cervix squamous cell carcinomas in human clinical 
examination (Li, Tang et al. 2014). In the animal models, doubling the Myc expression 
could also result in faster tumorigenesis and more serious tumor in the Myc induced T-
cell tumors in transgenic mice(Smith, Bath et al. 2006). In transgenic zebrafish liver 
tumor models generated by other oncogenes, such as kras and mouse Myc, tumor 
incidence and size are also related with oncogene expression level(Nguyen, Emelyanov et 
al. 2011; Nguyen, Emelyanov et al. 2012; Li, Zheng et al. 2013). Interestingly, the 
mycAG transgene expression in “Ascites” tumor was not very high. Usually, ascites is 
the consequence of the imbalanced osmotic pressure which is normally maintained by the 
hepatocytes synthesized protein albumin. Thus the ascites may indicate the dysfunction 
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of hepatocytes during fast onset of tumor, and the decrease expression of the transgene 
might also reflect these damages to hepatocytes. 
The possible reason for the divergent phenotypes with the same mifepristone induce 
condition could be multiple transgene insertions. As indicated in Table 3-1 and Table 3-2, 
F1 mycAG transgenic fish harbor at least two copies of the transgene. In addition, the 
transgenic fish were maintained by incrossing, and thus the genotypes of their offspring 
could be a mixture with single or multiple transgenic copies. Moreover, although all the 
transgenic fish adopted in this project were from the AB strain, individual differences 
might still exist and thus affect the sensitivity to oncogene expression. Finally, the 
integration of transgene into the genome may also affect the expression of nearby 
endogenous genes which may be involved in tumor progression and also change the 
tumor phenotypes. 
It is also notable that, although the divergent expression levels in individual mycAG 
transgenic fish result in different tumor types, at the tumor initiation stage within the first 
month, all the transgenic fish exhibit uniform transformation and rapid proliferation of 
hepatocytes. This might indicate that to initiate a tumor, the oncogenic expression 
threshold of myca is not very high. However, sustained high level expression of 
oncogene might be necessary for tumor progression and especially for development of 
severe tumor types. 
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4.4.3 mycAG Caused Zebrafish HCC Exhibited Some Traits Similar to Human 
These tumor phenotypes observed in mycAG zebrafish model exhibit some traits highly 
similar to human clinical cases. For example, ascites is frequently observed in HCC/liver 
cirrhosis and considered as an indicator of poor prognosis in human (Moore, Wong et al. 
2003; Hsu, Lee et al. 2012; Alswat, Sanai et al. 2013). Late stage HCC, large tumor 
burden, cirrhosis and vascular invasion are all causes of ascites formation(Hsu, Lee et al. 
2012). The observed ascites in zebrafish might equal to Grade 3 ascites in human which 
is the most serious grade with “marked abdominal distension” (Moore, Wong et al. 2003). 
However, in contrast to human cases, ascites in zebrafish only rapidly emerged at the 
early stage of tumor formation and gradually diminished after 2 mpi. Moreover there 
were also no evidences of tumor invasion and cirrhosis found from samples within 2 mpi. 
Hence, as mentioned before, the ascites phenotype in this zebrafish phenotype might be 
possibly due to the dysfunction of hepatocytes in the fast tumor progression. In addition, 
MYC expression has been found in the ascites-derived mononuclear cells in human 
ovarian tumors (Di, Duiveman-de Boer et al. 2013). Although lack sufficient evidence, it 
might be possible that zebrafish myca was also involved in the process of ascites 
formation.  
Cirrhosis is usually a major cause of HCC in human (Tsochatzis, Bosch et al. 2014), but 
in this zebrafish liver tumor model, it arose in late stage of the tumor progression. After 
the ascites phenotype diminished and solid tumors formed around 2 mpi, fibrosis-like 
cells appeared locally and typical cirrhosis similar to human was observed in these 
zebrafish liver tumors, and typical cirrhosis formed after a long time induction of 8 mpi/ 
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9 mpi, as shown in Figure 3-21. The formation of cirrhosis includes chronic inflammation 
and is the consequence of the increase of extracellular matrix and stromal cells. In human, 
the sustained activation of specialized liver mesenchymal cell, the hepatic stellate cells 
(HSCs), plays a critical role in liver cirrhosis formation. In response to pathologic 
changes, including tumorigenesis, HSCs can be rapidly transformed into myofibroblasts 
and fibroblasts, and at the mean time secrete extracellular matrix deposition to form 
cirrhosis (Kamal G. Ishak 2001; Wang and Chen 2013; Tsochatzis, Bosch et al. 2014). 
Direct evidence of Myc causing HSCs activation has also been found in the alb-
myctg mouse liver tumor model(Nevzorova, Hu et al. 2013). However, so far there is 
insufficient evidence to support the existence of HSCs and their participation in cirrhosis 
formation in fish(Yin, Evason et al. 2012). The observation of cirrhosis in this mycAG 
transgenic zebrafish liver tumor not only verified again the conservation of zebrafish with 
human in disease development, but also provided a possible proof of HSCs in the fish 
species.   
Moreover, the chronic changes of the liver mircroenvironment during tumor progression 
also benefit neoangiogenesis. Similar to human HCC(Zhu, Duda et al. 2011), 
angiogenesis was also observed in this mycAG transgenic zebrafish liver tumors which 
was manifested as prominent blood vessels on the surface of “Hemorrhage” tumors and 
increased vessel density in histology, as shown in Figure 3-18. As a cancer hallmark, the 
switch-on of angiogenesis meets the sustained requirement of tumor for nutrition and 
oxygen, and therefore it also indicated the liver tumor of this mycAG transgenic fish 
progressed in a rapid pace(Hanahan and Weinberg 2011). 
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4.4.4 mycAG was not Robust Enough to Cause Complete Metastasis 
Cirrhosis and angiogenesis also provide favorable environment for tumor invasion and 
metastasis; however, evident invasion to the other organs or ectopic hepatic tumor cells 
were not observed in histological examinations in this mycAG transgenic model till 9 
mpi. Nevertheless, “Epithelial-Mesenchymal Transition” (EMT), the sign of early 
prepare for metastasis has been found in 8 to 9 mpi fish tumors.  
Epithelial cells, such as hepatocytes, are regularly lined in layer or densely packed like 
wall-brick. Therefore the apparatus cell junctions to maintain the adhesion of cells with 
each other or the attachment to the extracellular matrix (ECM) are abundant in epithelial 
cells membrane (Stepniak, Radice et al. 2009). In contrast, mesenchymal cells are 
characterized by their loose association and increased mobility, and thus rare cell 
junctions exist in their membrane. In the tumors origin from epithelial tissues, such as 
HCC, reprogram from polarized epithelial cells to motile mesenchymal cells is the first 
and necessary step for metastasis(Thiery, Acloque et al. 2009). As the major component 
of epithelial adhesion junction apparatus, E-cadherin in the HCC tumors in 8 to 9 mpi 
mycAG transgenic fish lose from the membrane, as shown in Figure 3-22, which 
indicated the tumor cells were undergoing EMT process and their mobility was 
increasing. 
In addition to the loss of E-cadherin, translocation of β-catenin to nucleus was also 
observed in mycAG transgenic fish (Figure 3-22). β-catenin is another important 
component of adhesion junction diminished in the EMT process(Stepniak, Radice et al. 
2009), and moreover, β-catenin also acts as a transcription factor and serves for the 
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oncogenic WNT signaling pathway. Therefore its translocation from cell membrane to 
nucleus is not only a sign of EMT but also the demonstration of WNT signaling pathway 
activation. In addition, as another global cell fate regulator comparable to MYC, the 
activation of WNT signaling pathway suggests more aggravated status of tumor in this 
transgenic fish. 
However, metastasis is a complex process including multistage. Besides the dissociation 
with the original sites in EMT, the tumor cells also need the ability to survive in 
perplexing environment during migration, as well as the potential to site and grow in the 
new site(Joyce and Pollard 2009). In this study, it seems that mycAG transgene 
overexpression is still not sufficient to lead to successful metastasis. 
4.5 Oncogene Addiction and Tumor Regression 
In this zebrafish mycAG transgene caused HCC model, rapid disappearance of mycAG 
transgene expression was observed in the 6 mpi zebrafish livers after the removal of 
mifepristone. All the tumors of the four divergent phenotypes regressed rapidly and 
hepatocytes appeared to revert to a normal phenotype, as shown in Figure 3-30, 31, 32. 
Therefore, it indicates that the HCC status is addicted the sustained overexpression of 
zebrafish myca. Moreover, the overall regression of transgenic mycAG caused liver 
tumors might also suggest that no other critical mutations responsible for tumorigenesis 
and maintenance had occurred up to 6 mpi. 
Apoptosis is the major event happened in tumor regression process (Weinstein 2002) 
which was also observed in this mycAG transgene caused tumor regression. Therefore, it 
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is reasonable that mutation of genes promoting apoptosis may impede the tumor 
regression after the removal of initial oncogene. TP53 is an important promoter of 
apoptosis, and in the previous study we have shown that zebrafish tp53M214K loss of 
function could prevent the mycAG-caused apoptosis. TP53 mutation preventing tumor 
regression has also been observed in the mice hematopoietic tumors (Giuriato, Ryeom et 
al. 2006). However, it could not interrupt tumor regression in this transgenic mycAG 
HCC model. Significant increase of apoptosis, as serious as in mycAG transgenic fish 
without tp53 mutation, still had been observed in the regression process in AG53 fish 
liver, as shown in Figure 3-33. One explanation to this difference with other mice 
hematopoietic tumor could be the dissimilarity of tumor and animal types. But it is more 
likely that the mycAG transgene diminishment-caused apoptosis might also involve 
pathways independent of tp53.  
4.6 Summary and Conclusion 
In this study, we successfully applied the LexPR-mifepristone inducible expression 
system in establishment of a zebrafish liver tumor model and demonstrated its convenient 
and effective control of transgene expression in zebrafish liver. Taking advantage of the 
inducible expression system, we conducted a comparative study of the oncogenicity of 
zebrafish myca and mycb. For the first time, we showed that although these two zebrafish 
myc paralogs have distinct expression in zebrafish liver, both of them are oncogenic. 
Cancer development from uncontrolled proliferation to serious malignant lesion is a 
complicated process which involves a series of mutations accumulated over time (Meza, 
Jeon et al. 2008). The “Driver” mutations which provide the first proliferation and growth 
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advantages are the impetus of tumor initiation and progression, and usually are also the 
target of therapy. Besides, many other mutations occurred during tumor progression, 
named as “Passenger”, which have no apparent selective growth advantages are also 
found in tumor genomes. Therefore, it is extremely important to distinguish “Driver” 
mutations and “Passenger” mutations. In transgenic mouse model, expression Myc alone 
only resulted in chronic proliferation and increase of tumor incidence(Murakami, 
Sanderson et al. 1993; Calvisi and Thorgeirsson 2005). As MYC activation induced 
apoptosis has also been observed in many cell lines and transgenic models(Hoffman and 
Liebermann 2008; Larsson and Henriksson 2010), people may doubt the oncogenicity of 
Myc and its position in tumor initiation. In this study, with the expression of transgenic 
zebrafish myca and mycb, we observed very fast tumor growth and serious phenotypes, 
which demonstrated that both tow zebrafish myc paralogs, are robust “Driver” oncogenes 
in hepatocarcinogenesis.  
In addition, according to the cancer hallmarker theory, a successfully developed tumor 
generally possess eight characteristics: sustained proliferation, unlimited growth, resisted 
cell death, immortal replication, angiogenesis, metastasis, reprogrammed metabolism and 
destructed immune response(Hanahan and Weinberg 2011). Therefore, the oncogene 
with a broader spectrum of functions involving more tumor hallmarks could prone to 
have strong oncogenicity independently. Myc is a transcription factor regulating a wide 
spectrum of genes which participate in almost all the aspect of cellular process. Our data 
suggest a broad oncogenicity spectrum of zebrafish myca and its deep involvement in all 
aspects of tumor development. The tumor status is still completely relied on transgenic 
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mycAG sustained overexpression. Although some side mutations might happen during 
tumor progression, disturbance to the transgenic mycAG expression will cause serious 
apoptosis and fast regression of the tumor, which might be independent of tp53. 
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